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 Cell surface harbors rich information regarding the status of cell health. Being able 
to monitor and detect its changes in response to stimuli will provide crucial information in 
drug discovery, disease diagnosis, and human health. Despite the efforts and breakthroughs 
made possible through the specific sensing approach, there are significant challenges in 
extracting the information on the cell surface in a quantitative and reliable way. To address 
this challenge, I took the approach of array-based, hypothesis-free sensing in which the 
engineered sensors selectively interact with target analytes, producing a distinct pattern of 
response that enables analyte identification. This signature-based pattern recognition is 
particularly powerful in identifying the subtle changes on complex analytes (e.g. cell 
surfaces), rather than identifying specific elements within them. In this dissertation, I have 
applied such sensing strategy to facilitate the drug discovery process with the goal of 
rapidly identifying potential therapeutic candidates. Specifically, I utilize nanomaterials 
and polymers to construct effective nanosensors to phenotype mammalian cells. The first 
part of the thesis focuses on sensing a key target in cancer: cancer stem cells (CSCs). 
Utilizing a supramolecular nanoparticle-fluorescent protein sensor array, we successfully 
 
 viii 
discriminated breast CSCs from non-CSCs, as well CSCs that had differentiated in vitro. 
Furthermore, we integrated array-based sensing with nanoparticle surface engineering to 
screen and identify a candidate nanoparticle that not only induces CSC differentiation but 
also renders them more susceptible to drug treatment. The second part of the thesis 
demonstrates the power of array-based sensing in immunotherapies with the example of 
profiling different macrophage polarization states. I developed a novel sensor system that 
employs only two sensor elements to generate a high data density of five channels. Such 
high-content information enabled us to quantitatively discriminate among major 
macrophage polarization states as well as multiple less-characterized phenotypes in a 
matter of minutes. Overall, array-based sensing provides a simple and robust tool for cell 










ABSTRACT ...................................................................................................................... vii 
 
LIST OF TABLES ............................................................................................................. xi 
 




1. INTRODUCTION ...........................................................................................................1 
1.1 Biosensing: specificity v.s. selectivity .....................................................................1 
 1.2 Cell phenotyping using array-based sensors ............................................................3 
 1.2.1 Challenges of specific sensing in cell phenotyping ........................................3 
 1.2.2 Opportunity of cell phenotyping using selective array-based sensors ............4 
 1.3 Profiling phenotypically plastic cells: cancer stem cells .........................................6 
 1.3.1 EMT and phenotypic plasticity of CSCs ........................................................6 
 1.3.2 Partial EMT and CSC heterogeneity...............................................................7 
 1.3.3 EMT promotes stemness in CSCs...................................................................8 
 1.3.4 Differentiation therapy to combat CSCs .........................................................9 
1.4 Array-based sensing in high-content screening and drug discovery .....................11 
1.5 Dissertation overview ............................................................................................13 
1.6 References ..............................................................................................................14 
 
 
2. RAPID PHENOTYPING OF CANCER STEM CELLS USING MULTICHANNEL     
NANOSENSOR ARRAYS ...............................................................................................19 
2.1 Abstract ..................................................................................................................19 
 2.2 Introduction ............................................................................................................19 
2.3 Result s....................................................................................................................22 
 2.3.1 Complexation of nanosensor.........................................................................22 
 2.3.2 Sensing of established CSC model ...............................................................23 
 2.3.3 Development of a phenotypic plastic CSC model ........................................25 
 2.3.4 Detection of phenotypic changes on CSCs ...................................................26 
 2.3.5 Sensing of patient-derived xenografts ..........................................................28 
2.4 Discussion ..............................................................................................................29 
2.5 Conclusion .............................................................................................................31 
2.6 Experimental section ..............................................................................................32 
2.7 References ..............................................................................................................36 
 
3. DIFFERENTIATION OF CANCER STEM CELLS THROUGH NANOPARTICLE 
SURFACE ENGINEERING .............................................................................................40 
 
 x 
3.1 Abstract ..................................................................................................................40 
3.2 Introduction ............................................................................................................40 
3.3 Results and discussion ...........................................................................................44 
 3.3.1 AuNPs with tunable surface functionality for structure-activity studies ......44 
 3.3.2 Identification of two sub-populations of transformed mammary epithelial 
 cells that differ in CSC properties ..........................................................................45 
 3.3.3 Screening for NP-induced CSC differentiation ............................................47 
 3.3.4 Identifying phenotypic alterations from C6NP treatment .............................51 
 3.3.5 Increased ROS levels are a consequence of C6NP treatment .......................52 
 3.3.6 Sensitization of CSCs for drug treatment .....................................................55 
3.4 Conclusion .............................................................................................................57 
3.5 Experimental section ..............................................................................................57 
3.6 References ..............................................................................................................62 
 
4. HIGH-CONTENT AND HIGH-THROUGHPUT IDENTIFICATION OF 
MACROPHAGE POLARIZATION PHENOTYPES .......................................................67 
4.1 Abstract ..................................................................................................................67 
4.2 Introduction ............................................................................................................67 
4.3 Result s....................................................................................................................72 
 4.3.1 Supramolecular assembly of sensor ..............................................................72 
 4.3.2 Discrimination of M1 and M2 subtypes using RAW 264.7 cells .................74 
 4.3.3 Discrimination of M1 and M2 subtypes with primary macrophages ...........78 
 4.3.4 Discrimination of macrophages exposed to conditioned media from different 
 cancer cells .............................................................................................................80 
4.4 Discussion ..............................................................................................................82 
4.5 Conclusion .............................................................................................................84 
4.6 Experimental section ..............................................................................................85 
4.7 References ..............................................................................................................91 
 
5. CONCLUSION AND OUTLOOK ................................................................................95 
5.1 Potentials of array-based sensing in biomedical research......................................95 
5.2 The role of α6β4 integrin in CSC differentiation ...................................................96 
5.3 Alternative CSC detection methods and screening application .............................99 
5.3 Tumor microenvironment ....................................................................................100 






LIST OF TABLES 
Table Page 
 
3.1. Summary of the distance between any two tested groups in HMLER model system ......50 
3.2. Quantification of synergy for combination therapy on HMLER-CSCs ...........................56 
4.1. Mechanisms and effects of in vitro macrophage polarization of macrophages via 






LIST OF FIGURES 
Figure Page 
 
1.1. Schematic illustration of the working principle of array-based sensing .............................3 
1.2. Schematic illustration of how array-based sensing mimics the human olfactory system...5 
1.3. The process of epithelial-mesenchymal transition ..............................................................6 
1.4. Target-based versus phenotypic drug discovery approach ...............................................12 
2.1. Schematic illustration of signature-based sensing of CSCs ..............................................22 
2.2. Discrimination of CSCs from the MCF-10A ER-Src system using BenzNP-FP 
nanosensors ..............................................................................................................................24 
2.3. Correct unknown identification (CUI) of blinded cell mixture samples from the MCF-
10A ER-Src system using either three FP or individual FP channel .......................................25 
2.4. Workflow of generating reversible S1 model ...................................................................26 
2.5. Discrimination of CSCs, non-CSCs and de-CSCs from S1 system using BenzNP-FP 
nanosensor ...............................................................................................................................27 
2.6. Isolation, characterization, and discrimination of primary CSCs from patient-derived 
xenografts ................................................................................................................................28 
3.1. Schematic illustration of the integration of nanoparticle design and hypothesis-free 
sensing ................................................................................................................................42 
3.2. Characterization of HMLER subpopulations....................................................................45 
3.3. Schematic illustration of sensor composition and selective interactions with cell surfaces .
  ................................................................................................................................47 
3.4. Cytotoxicity of tested NPs on HMLER-CSCs ..................................................................47 
3.5. Sensing screen in capturing phenotypic changes of CSCs under different AuNP 
treatment ................................................................................................................................49 
3.6. Sensing screen in capturing phenotypic changes of CSCs (from MCF10A-ER-Src 
system) under different AuNP treatment .................................................................................50 
3.7. MET evaluation of HMLER-CSCs treated with 100 nM C6NP for 72 hrs ......................51 
 
 xiii 
3.8. ROS production of CSCs and NCSCs treated with C6NP ...............................................52 
3.9. ROS production of CSCs treated with different types of NPs for either 30 min or 4 hrs .53 
3.10. mRNA quantification of α6A splicing gene when CSCs were treated with 100 nM 
C6NP with or without ROS inhibitor NAC .............................................................................54 
3.11. Validation of C6NP on CSCs and NCSCs isolated from a patient-derived xenograft 
using CD24 and CD44 markers ...............................................................................................55 
3.12. IC50 of 2DG alone or in combination with C6NP on HMLER-CSCs or NCSCs ..........56 
3.13. Intracellular uptake of AuNPs on HMLER-CSC quantified by ICP-MS .......................60 
4.1. Schematic illustration of phenotyping macrophage activation states using array-based 
sensor ................................................................................................................................72 
4.2. Fluorescence titrations and quenching between C3-Gu-Py and EGFP ............................73 
4.3. RAW 264.7 macrophage activation confirmed by RT-PCR ............................................75 
4.4. RT-PCR quantification of M2 state in IL-10 activated RAW 264.7 macrophages ..........76 
4.5. Discrimination of RAW 264.7 macrophages activated by M1 or M2 subtype stimuli 
using sensor complexes............................................................................................................77 
4.6. RT-PCR quantification activated primary bone marrow-derived macrophages...............79 
4.7. Discrimination of M1 and M2 subtypes of bone marrow-derived macrophages .............79 
4.8. RT-PCR quantification macrophages exposed to conditioned media from different 
cancer cells ...............................................................................................................................81 
4.9. Discrimination of macrophage cells cultured under exposure to conditioned media from 
different cancer cell types for 48 h ..........................................................................................82 
4.10. Hydrodynamic size of PONI-C3-Gu-Py polymer and polymer-GFP assembly in 10mM 
HEPEs buffer ...........................................................................................................................85 
4.11. TEM image of PONI-C3-Gu-Py polymer and polymer-EGFP assembly in 10 mM 
HEPEs buffer ...........................................................................................................................86 






1.1 Biosensing: specificity v.s. selectivity 
Sensing is a crucial process in our daily lives, monitoring our health and governing 
our safety. Nowadays, sensors are widely used in industry, medicine, and technologies to 
ensure a good quality of life. In order to build an efficient biosensor, two essential processes 
must occur: analyte recognition and signal transduction. Initially, the recognition element 
in the sensor needs to bind or interact with the target analyte. This could occur either 
through specific or selective interactions. Second, the recognition event between analyte 
and each receptor in the array needs to be transduced to a measurable outcome such as a 
colorimetric, fluorogenic, and electrochemical signal. Lastly, appropriate statistical 
methods need to be implemented to the collected data for analyte classification or 
identification.  
Depending on the type of interactions that the sensor elements have with target 
analytes, two major types of sensing exist: specific and selective sensing. In the biological 
world, most sensing happens through specific interactions via a lock-and-key format. 
Specific sensors, as the name suggests, bind only to a single analyte regardless the presence 
of other components. The key criteria of an efficient specific sensor is the use of high 
affinity recognition element including antibodies,1 lectins,2 aptamers3, and enzymes.4 This 
approach has been successfully developed into many commercially available products such 
as pregnancy tests,5 diabetic monitoring device6 and so on. Perhaps, the most profound 
application of specific sensing is in the example of using biomarkers for disease diagnosis 
and treatment. Over the past few decades, a list of cell surface receptors with different 
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expression levels in cancer cells have been identified.7,8,9 As a result, a range of cancer 
detection methods (e.g. electromagnetic imaging, 10  immunostaining, 11  and flow 
cytometry 12  ) have been developed to sense the up- or down- regulation of these 
biomarkers. Furthermore, better understanding of how to design molecules that specifically 
bind to these biomarkers is crucial in developing efficient anticancer therapies. For 
instance, targeting ligands that have low binding affinity towards normal cells have been 
engineered and attached to drug delivery vehicles to guide the systems to site-specific 
cancer cells, while avoiding off-target toxicity.13,14 
Specific sensing works the best the sensing environment is relatively simple with a 
minimum amount of cross-reactivity. However, most biological and physiological relevant 
samples are very complex, and the target analyte often co-exists with other molecules, 
making cross-reactivity in specific sensing unavoidable. Interestingly, the challenge of 
cross-reactivity in specific sensing presents the opportunity for selective sensing.  
Selective sensing or array-based sensing works through an entirely different 
principle than specific sensing, where cross-reactivity is the key feature. Array-based 
sensors have a set of receptors that are engineered to be semi-specific/selective to target 
analytes so that they are flexible to interact with different analytes or different components 
of the analyte. Such interactions then generate a unique pattern containing comprehensive 
information for each analyte (Figure 1.1).15 The cross-reactivity of the sensor receptors 
ensures that different aspects of the target analyte information can be extracted and used 
for classification and identification.16  It is particularly powerful when the sensing samples 
are complex and dynamic such as proteins in biofluids, 17  bacteria, 18  and mammalian 
cells. 19  Since the responses produced from array-based sensors often have a high 
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dimension, an additional step of data processing through statistical methodologies is often 
needed.  
 
Figure 1.1. Schematic illustration of the working principle of array-based sensing. Adapted 
from reference 15. Copyright (2021) Japan Society for Analytical Chemistry. 
 
1.2 Cell phenotyping using array-based sensors  
1.2.1 Challenges of specific sensing in cell phenotyping 
 
Cell phenotyping has become an important tool for understanding and treating 
cancers. Cell surface not only provides a physical barrier to the outside, but also reflects 
intracellular events. The components of the mammalian cell membrane have been found to 
exhibit different physicochemical properties among different cell types, as well as between 
healthy and disease cells.20,21,22 Therefore, being able to monitor and detect cell surface 
changes in response to external stimuli will provide crucial information in disease 
diagnosis and drug discovery.   
 Commonly used methods in studying cell surfaces are mainly through biomarkers. 
While providing useful information, biomarker-based strategies face a set of challenges. 
First, this approach requires a specific hypothesis in which the analyte-target interactions 
are well-understood. However, such information might take years of research work. If the 
biomarker is not known or well-characterized, it is difficult to design sensors with targeted 
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specificity. Second, as cells progress from normal to disease state, changes in multiple 
biomarker expression levels would occur, requiring a large number of antibodies built in 
the specific sensing method to achieve accurate disease diagnosis.23,24 In addition, many 
of the identified surface markers are shared between disease cells and normal cells at 
different expression levels, making off-target effect a challenging hurdle to overcome. 
Furthermore, cell phenotyping methods (e.g. flow cytometry, fluorescent imaging) usually 
involve multi-step processing of cells and specialized instrumentations, which are not only 
labor-intensive but also incompatible with high-throughput screening assays in drug 
development.   
1.2.2 Opportunity of cell phenotyping using selective array-based sensors  
 
The complex surface composition of intact living cells makes them excellent targets 
for array-based sensing. Array-based sensing is initially inspired by the mammalian 
olfactory system where a limited set of olfactory receptors can sense thousands of different 
odorants through cross-interactivity and pattern recognition. 25 , 26  Array-based sensing 
mimics such process by using synthetic materials including nanomaterials, polymers, and 
proteins. Unlike biomarker-based approach, array-based sensing utilizes a set of cross-
reactive receptors to selectively interact with target analytes, producing a distinct pattern 
of response for each analyte (Figure 1.2). The strategy is ideal for cell phenotyping because 
changes in cellular responses yield variations in surface composition (e.g., protein, lipids, 





Figure 1.2. Schematic illustration of how array-based sensing mimics the human olfactory 
system. Adapted from reference 26. 
 
Traditionally array-based sensing is widely used in non-biological samples such as 
explosives,30 volatile-organic compounds,31 metal ions,32 and environmental toxins.33 In 
the past few decades, however, there is an emerging trend of applying array-based sensing 
in complex biological analytes with the goal of advancing medicine. Much research work 
has looked to provide diagnostic information through cell surface profiles.34 A wide range 
of sensor arrays have been reported to detect the differences between non-cancerous, 
cancerous, and metastatic cell lines. For instance, Tao and coworkers utilized dual-ligand 
functionalized gold nanoclusters to construct a sensor array and achieved separation of ten 
triple-negative breast cancer cell lines from multiple patients, with varying degrees of 
metastasis.27 Recently, Kurita group designed a one-component sensor array using a 
dansyl-modified polylysine that not only differentiated eight types of human cell lines but 
could also differentiated the cell mixtures containing cells of different subtypes.35 
 
 6 
1.3 Applying array-based sensing in phenotypically plastic cells: cancer stem cells  
1.3.1 EMT and phenotypic plasticity of CSCs  
Epithelial-mesenchymal transition (EMT) is a normal process that enables cells to 
carry out essential functions such as wound healing and embryogenesis.36 During EMT, 
epithelial cells that are normally held together by tight cell-cell junctions gradually lose 
their assembly and become more spindle-like (Figure 1.3).37 Such changes in morphology 
is orchestrated by EMT-inducing transcription factors (ZEB, SNAIL, and TWIST) which 
inhibit the expression of epithelial genes (e.g. E-cadherin, cytokeratin) and activate the 
expression of mesenchymal genes (e.g. N-cadherin, Fibronectin). The resulting 
mesenchymal cells can also revert to their epithelial state via mesenchymal-epithelial 
transition (MET).38  
 
Figure 1.3. The process of epithelial-mesenchymal transition. Adapted from reference 37. 
 
Activation of EMT in carcinoma cells can lead to a population of cells with stem 
cell-like properties. These cells, termed as cancer stem cells (CSCs), have the ability to 
self-renew and differentiate into multiple lineages of cells that comprise the tumor.39 The 
plastic nature of CSCs is demonstrated in their ability to differentiate into non-CSCs and 
non-CSCs de-differentiate into CSCs. Interestingly, the interconversion between CSCs and 
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non-CSCs is not a two-state process, rather a spectrum of phenotypes can exist along the 
EMT spectrum. It is well documented that EMT activation can be induced by several 
signaling pathways including the transforming growth factor-β (TGFβ), WNT, and 
NOTCH pathways. Depending on the tumor type and the external stimuli received by cells, 
different EMT-transcription factors will be involved, resulting in multiple intermediate 
states.40,41 In addition, a diverse line of research has shown that partial EMT can give rise 
to CSCs expressing both epithelial and mesenchymal traits.42,43 As discussed earlier, most 
biomarker-based methods require a set of defined markers. The phenotypic plasticity of 
CSCs makes it challenging to target these intermediate states of CSCs. 
1.3.2 Partial EMT and CSC heterogeneity 
 A consequence of EMT activation is the enrichment of mesenchymal cells with 
stem cell properties, termed as CSCs. Interestingly, CSCs are not homogeneous, rather 
subpopulations with distinct functions have been reported.44,45 One contributor to CSC 
heterogeneity could be the degree of EMT activation. A common way of inducing EMT is 
by adding the growth factor TGF-β to cultured cells. In contrast to the shorter exposure 
time (a few days), which is routinely used by researchers, a recent study reveals that the 
prolonged exposure (weeks) to TGF-β stabilized cells in the mesenchymal state. The 
stabilized EMT gave rise to a larger CD44+CD24- stem cell population than cells under a 
shorter-exposure since the resulting mesenchymal cells could not be reverted to the 
epithelial state when TGF-β was withdrawn. 46  This suggests that when CSCs were 
enriched using TGF-β, cells reside in a more mesenchymal state but have the ability to 
revert to the epithelial state. Therefore, the CSCs generated are likely a mixed 
mesenchymal and epithelial populations. The heterogeneity of CSC is further evident in 
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the findings that the enriched mesenchymal cell population can be further stratified into 
subtypes with distinct morphology, EMT-associated gene expression, self-renewal and 
tumor initiating abilities.44,45 In addition, the reversibility of EMT program makes partial 
EMT a common phenomenon in both normal and carcinoma cells. Although partial EMT 
is important for cancer cells to gain motility during tumor invasion and dissemination,47 it 
also contributes to the complex of CSC heterogeneity. Since it is rare for cells to stay in a 
locked end of the EMT spectrum, fully mesenchymal or fully epithelial, CSCs generated 
through EMT are likely to have an intermediate level of EMT activation with a mixed 
expression of epithelial and mesenchymal traits. 48  
1.3.3 EMT promotes stemness in CSCs.  
 Stemness, the ability of cells to self-renew and form mammospheres from a single 
cell, is a key characteristic of CSCs. Although a number of studies have shown that EMT 
promotes stemness in a range of different tumor types including breast, colon, lung, 
pancreatic, and ovary carcinomas37, the detailed mechanisms remain unclear. 
Understanding the mechanism of how CSCs acquire stemness will offer insights on 
developing therapies targeting such property. Recent studies on several signaling pathways 
have revealed specific mechanisms of how EMT induces stemness. Specifically, Bmi1, an 
epigenetic regulator that is involved in chromosome silencing, has been shown to be at the 
regulating center of EMT-transcription factors (EMT-TF). In pancreatic cancer, research 
showed that EMT-TF Zeb 1 binds to the upstream promoter of miRNAs from the miR200 
family to repress their expression. Consequentially, this repression resulted in the removal 
of Bmi1 inhibition, which enables Bmi1 to execute its function in maintaining stem cell 
function.49,50 In addition to Zeb1, others have reported that another EMT-TF, Twist1, 
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directly upregulates Bmi1 expression by binding to the regulatory region of its promoter. 
The overexpression of Bmi1 induced EMT and resulted in an increase in tumor-initiating 
abilities in head and neck squamous cell carcinoma cells. Mechanistic studies using 
quantitative ChIP revealed that Bmi1 and Twsit1 participate in Bmi1-containing polycomb 
repressive complex to bind to the promoter regions of E-cadherin and p16INK4a (a cyclin-
dependent kinase inhibitor associated with senescence) 51  and further inhibit their 
expression.52 Collectively, these studies suggest that chromatin modification seems to be 
the main mechanism in which transcription factors (Snail,53 Zeb1 and Twist 1) affect EMT. 
These mechanistic studies open the possibility of targeting epigenetic regulators as an 
alternative way of treating CSCs. 
1.3.4 Differentiation therapy to combat CSCs 
When EMT occurs in carcinoma cells rather than normal cells, tumor cells become 
more aggressive and acquire resistance to chemotherapies and radiotherapies. Therefore, 
direct elimination of CSCs is challenging. Based on the observation of CSC plasticity, 
forcing CSCs to differentiation should diminish the frequency of CSCs, rendering tumors 
less aggressive and more responsive to conventional therapy. This strategy is known as 
differentiation therapy. Supported by the successful example of all-trans retinoid acid in 
treating acute promyelocytic leukemia, 54  differentiation therapy presents an effective 
treatment to overcome drug resistance in cancer.  
 There has been a widespread interest in identifying molecules that selectively target 
CSCs or promote their differentiation. Recently, many high-throughput screenings have 
reported promising small molecules that target specific signaling pathways involved in cell 
differentiation.  In 2016, Fang et al. screened a library of 16,000 synthetic compounds and 
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identified LF3 as an efficient inhibitor that disrupts the interaction between β-catenin and 
the transcription factor T-cell factor 4. Since the Wnt/ β-catenin pathway is deregulated in 
CSCs, such disruption resulted in overexpression of Wnt target genes.55 Another screen 
conducted in 2009 revealed Salinomycin as a potent molecule that selectively targets breast 
cancer stem cells. 56  In addition to small molecules, microRNA interference 57  and 
epigenetic modifications58have also demonstrated their ability to act on CSCs and induce 
differentiation. 
Despite the progress in identifying novel differentiation therapeutics, the discovery 
process is slow and inefficient. Among thousands of screened compounds, only a few of 
them showed promising activities.59,60 The inefficiency in these screenings is likely due to 
the hypothesis-driven design. Only well-understood molecular pathways are being used to 
design the screening assays. However, the detailed biological mechanisms in cancer stem 
cell biology remain to be elucidated.61 More significantly, hypothesis-driven strategies 
limit detection to a pre-defined phenotype, potentially failing to detect other differentiated 
phenotypes.  
 Based on the limitations in current knowledge of CSC biology, it is less ideal to 
employ the specific target interaction approach to identify CSC differentiation inducers. 
Instead, the array-based sensing approach described in this dissertation does not require 
any prior-knowledge of target analytes. The signature generated from the sensor can be 
used to rapidly screen compounds that induce CSCs to a phenotypic state that is more 
susceptible for conventional treatment. In the following chapters, I will describe how we 
used array-based sensors as a high-throughput and high-content screening tool to identify 
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molecules that promoted the differentiation of CSCs. It is our hope that differentiation 
therapy will bring promises to combat cancer. 
1.4 Array-based sensing in high-content screening and drug discovery 
 A very different application of array-based cell sensing from diagnostics is to 
monitor the response of cells when exposed to an environmental stimulus such as a drug. 
High-throughput screening (HTS) and high-content screening (HCS) using cell-based 
assays are increasingly integrated in various aspects of the drug discovery pipeline.62,63 
HCS aims to measure multiparameter change of cells caused by screening compounds. It 
is highly utilized in the phenotypic drug discovery approach to identify potential drug hits. 
Unlike target-based approach, it first subjects cells to a library of screening compounds 
and uses phenotypic assays to help identify lead compounds that induce cells to a disease 
state (Figure 1.4).64 Imaging-based HCS is a powerful tool in evaluating cell status by 
collecting multiple cell features such as transcriptional,65 genomic,66 proteomic, 67 and 
metabolomic68 information. However, many of the cell-based assays in HCS are limited 
by  multi-step processing of cells prior to analyses (e.g. staining, fixing and imaging), and 
an incomplete understanding of biomolecular pathways for correlating drug and 
response.66,69 In addition, because most HCS assays require microscopic instrumentation 




Figure 1.4. Target-based versus phenotypic drug discovery approach. Adapted from 
reference 54. 
 
The goal of phenotypic-based HCS is to create a unique fingerprint of cell states 
and use it as a reference. As discussed in section 1.2, array-based sensing works through 
selective interactions between the sensor elements and cell surface functionalities to 
generate a signature for each cell state. Under external stimuli, such as drug candidates, 
any changes on the cell surface (glycoproteins, lipids, proteins etc.) could interact with the 
sensor array generating a detectable signal, which makes this method hypothesis-free and 
non-bias. By comparing the signature of cells under treatment with that of untreated cells, 
one can quickly distinguish if the screened compounds have any significant impacts and 
would be interesting targets for downstream evaluations. The hypothesis-free feature 
enables such sensing strategy to be particularly powerful in distinguishing subtle changes 
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in complex bioanalytes (e.g. cells), rather than identifying specific elements within them. 
To demonstrate the utility of array-based sensors HCS, Rana et. al. developed a gold 
nanoparticle-fluorescent protein sensor array and applied it to cells exposed to one of 
fifteen different anti-cancer drugs featuring seven different drug mechanisms. The sensing 
results showed distinct patterns for each treated cell line, which could be further clustered 
into the hypothesized drug mechanism, and novel drugging routes were also elucidated.70 
Another advantage of utilizing array-based sensing in HCS is that the synthetic 
design space allows one to quickly obtain a high-content information of the target analyte. 
It is possible to engineer multiple different recognition elements so that different types of 
cell functionalities can interact with the sensor.71 In addition, more output channels can be 
obtained by modifying the sensor design. For instance, using host-guest interaction 
between benzylammonium-functionalized nanoparticle and cucurbit[7]uril moiety, Ngoc 
et. al. doubled the output channels from three to six. The increased amount of information 
gathered from the sensor array allowed successful discrimination of cells by their 
tumorigenicity.72 
1.5 Dissertation overview  
 In this dissertation, I investigate different ways that array-based sensing can be 
applied in drug discovery with a particular focus on cancer stem cell therapy and 
immunotherapy. In Chapter 2, I describe a turn-on sensing system composed of gold 
nanoparticles and three different fluorescent proteins through supramolecular interactions. 
Using this sensor array, we were able to rapidly profile phenotypically distinct CSC states 
and monitor their fate as CSC differentiate. This sensor platform provides a tool in 
screening applications for better therapeutic design. Next, we combined array-based 
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sensing strategy with nanoparticle surface engineering to screen a library of nanoparticles 
with varying degrees of hydrophobicity (Chapter 3). This is a proof of principle that array-
based sensing can be adapted in high-content screenings to facilitate the drug discovery 
process. Through the screen, one nanoparticle was identified as a potential drug candidate 
that not only promoted CSCs to differentiate but also sensitized cells for therapeutic 
treatment. Further mechanistic studies suggested that such differentiation was induced by 
altering the splicing variant of α6 integrin subunit through up-regulation of reactive oxygen 
species in CSCs. In the last part of the thesis, we expanded and applied array-based sensing 
to a different class of cell analytes, immune cells. Specifically, we developed a novel sensor 
platform that gives out high-content information regarding macrophage polarization states. 
By successfully discriminating among different subtypes of M1 and M2 states, we not only 
validated the potentials of array-based sensing in immunotherapy but also the 
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RAPID PHENOTYPING OF CANCER STEM CELLS USING MULTICHANNEL 
NANOSENSOR ARRAYS 
2.1 Abstract 
Cancer stem cells (CSCs) contribute to multidrug resistance, tumor recurrence and 
metastasis, making them prime therapeutic targets. Their ability to differentiate and lose 
stem cell properties makes them challenging to study. Currently, there is no simple assay 
that can capture and trace the dynamic phenotypic changes on the CSC surface. Here, we 
report rapid discrimination of breast CSCs from non-CSCs using a nanoparticle-
fluorescent-protein based sensor. This nanosensor was employed to discriminate CSCs 
from non-CSCs, as well as CSCs that had differentiated in vitro in two breast cancer 
models.  Importantly, the sensor platform could also discriminate CSCs from the bulk 
population of cells in patient-derived xenografts of human breast cancer. Taken together, 
the results obtained demonstrate the feasibility of using the nanosensor to phenotype CSCs 
and monitor their fate. Furthermore, this approach provides a novel area for therapeutic 
interventions against these challenging targets. 
2.2 Introduction 
The complex geno- and phenotypic heterogeneity of tumors is reflected in the 
observation that tumor cells within a given cancer differ in their morphology, proliferative 
capacity, sensitivity to therapeutic agents and metastatic potential. Although quantitative 
analysis of phenotypic markers is an essential tool for drug discovery,1 it can be challenging 
because of tumor heterogeneity. One of the most telling aspects of such nature is that only 
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a subset of cells within a tumor are capable of initiating a new primary tumor or metastasis.2 
These cells are referred to as cancer stem cells (CSCs). They have the ability to self-renew 
and differentiate into multiple lineages, metastasizing and populating new tumors.3 CSCs 
are highly resistant to standard chemotherapeutic strategies and are considered prime 
drivers of tumor recurrence and metastasis, making them important therapeutic targets.4,5 
CSCs present in solid tumors are often de-differentiated and exhibit properties of 
an epithelial-to-mesenchymal transition (EMT). 6 , 7  In fact, EMT can enrich a CSC 
population, a process associated with cancer progression and metastasis.8,9 CSCs are also 
inherently plastic and they can differentiate i.e., undergo a mesenchymal-epithelial 
transition (MET), in response to stimuli from the microenvironment and other factors.10,11 
This process results in loss of stem cell properties, which make them even more difficult 
to detect and monitor. Interestingly, however, the EMT and MET may not be all-or-none 
responses, but rather multi-stage and reversible processes involving intermediate 
states.12,13 During each transition state, both genomic and phenotypic changes can occur, 
with concomitant alterations in their behavior and response to drugs.14 This complexity of 
CSC phenotypes even within the same cancer creates a challenge when profiling CSCs 
from individual tumors.  
Current methods of phenotyping cells are mainly through fluorescent imaging and 
flow cytometry.15,16 While providing useful information, these methods are limited in a 
few aspects: expensive instrumentation, specific antibodies, and burdensome data 
collection and analysis. Moreover, current strategies rely heavily on cell surface 
markers.17,18,-19 Such biomarker-based approaches, however, are hindered by ambiguity 
and end-point evaluation. For instance, CD133 was thought to be a suitable marker for 
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colon CSCs, but alternative sensing modalities show this biomarker to be unreliable.20,21  
In addition, evidence has shown that a partial EMT gives rise to hybrid cells expressing 
both epithelial and mesenchymal markers.13,22 Since end-point biomarker evaluation only 
targets one phenotype, using this approach is likely to miss any intermediate states. Thus, 
there is an urgent need for a simple and general method to phenotype and trace the dynamic 
changes that occur within populations of CSCs. 
Nanotechnology in combination with natural science has emerged to become a 
powerful tool for investigating challenging biological questions.23,24 Inspired by the human 
olfactory system, chemical nose sensing was developed as a hypothesis-free, signature-
based tool to identify complex bioanalytes. 25 , 26 ,- 27  Gold nanoparticles (AuNPs) with 
tunable surface functionality and strong quenching ability28 are ideal for constructing 
nanosensors. Nanoparticle-based sensor arrays can be engineered to selectively interact 
with a target analyte, generating a unique response signature. Since no specific recognition 
is involved in the process, extensive pre-knowledge of analytes is not required, making it 
a hypothesis-free approach. Once trained, nanosensors can quickly identify target analytes 
through pattern recognition and results can be obtained within minutes. Successful 
implementation has been shown in a wide range of biomolecules including proteins,29 
bacteria,30 and mammalian cells.25  
In this paper, we employ an array-based strategy to profile CSCs and monitor their 
phenotypic alterations (Figure 2.1). The nanosensor used here is composed of a 
functionalized gold nanoparticle (AuNP) and three fluorescent proteins (FP) of which the 
fluorescence is initially quenched by AuNP but restored upon addition of cells. We tested 
our sensor against CSC models created both in vitro and in vivo, demonstrating a feasible 
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approach to detect differentiation and other phenotypic changes for both screening 
applications and personalized diagnostics. 
 
Figure 2.1. Schematic illustration of signature-based sensing of CSCs. (A) Equimolar 
amount of three fluorescent proteins are incubated with Benzyl-AuNP forming BenzNP-
FP complexes. (B) Upon the additional of cells, fluorescent proteins are displaced and 
turned on by cell surface. Populations of CSCs, non-CSCs and CSCs that have 
differentiated and lost stem cell properties (de-CSCs) interact differentially with sensor 
elements, resulting in unique fluorescent patterns. 
2.3 Results  
2.3.1 Complexation of nanosensor. The sensor array used here is composed of a 
benzyl headgroup-terminated AuNP (BenzNP) and three types of fluorescent proteins 
(EGFP, EBFP, and tdTomato) as shown in Figure 2.1A. The cationic BenzNP binds 
strongly with anionic fluorescent proteins, resulting in fluorescence quenching. Upon 
incubation with cells, cell surface functionalities compete with fluorescent proteins for 
AuNP binding. The released fluorescent proteins can then freely emit light, simultaneously 
giving out three-channel information in one well from the microplate. We hypothesized 
that CSCs and non-CSCs would interact differently with the BenzNP-FP supramolecular 
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complexes, resulting in the generation of unique fluorescence patterns that could be used 
to profile CSC states (Figure 2.1B). 
2.3.2 Sensing of established CSC model. We first used a system that involves Src-
transformation of mammary epithelial (MCF10A) cells to test our hypothesis. Upon 
transformation, the frequency of CSCs (CD44high/CD24low) increases significantly. 31 
Interestingly, though, this CD44high/CD24low population is comprised of two distinct 
populations that differ in their differentiation status and stem cell properties. 32   The 
epithelial population (EPTH) is comprised of differentiated cells and lacks stem cell 
properties. The mesenchymal population (MES) is comprised of de-differentiated cells and 
exhibits stem cell properties (self-renewal, expression of stem cell genes, mammosphere 
formation and tumor initiation). The two subpopulations were isolated using previously 
reported procedures32 and seeded at a density of 104 cells/well in a 96-well microplate for 
24 hours. Subsequently, an equimolar amount of BenzNP and three FPs were mixed at 
room temperature to form the nanosensor. Cells were washed once with phosphate buffered 
saline (PBS) and incubated with the nanosensor for 30 minutes before fluorescent 
measurement. The changes in fluorescence responses were statistically analyzed using 
linear discriminate analysis (LDA).  
As shown in Figure 2.2, the MES population that harbors CSC properties was 
completely discriminated from the EPTH population that lacks CSC properties with 100% 
correct classification (two shaded ellipses).  An important issue is whether our nanosensor 
could detect CSCs in a heterogeneous population of cells.  To address this question, MES 
and EPTH cells, which had been cultured either separately or as a mixture, were incubated 
with the nanosensor. We found that the nanosensor could discriminate the relative 
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proportion of CSCs with a high level of confidence (Figure 2.2). Significantly, the sensor 
detected a corresponding trend across all the heterogeneous populations. Cross-validation 
among 0%, 50% and 100% CSC groups showed 100% correct classification. Blinded cell 
mixture samples were tested for unknown identification among the three groups. 96% 
accurate unknown identification was achieved with only one case of 0% CSC misclassified 
as 50% CSC. To further evaluate the importance of each FP channel in our sensor, 
identification of unknowns using individual FP were carried out. As shown in Figure 2.3, 
each channel contributes to the identification to certain extent. However, when combined 
all together, it reaches the highest identification accuracy. 
 
Figure 2.2. Discrimination of CSCs from the MCF-10A ER-Src system using BenzNP-FP 
nanosensor. Normalized fluorescent intensities against sensor only (I/I0) were obtained 
with nanosensor against different ratios of the MES (harboring CSCs) and EPTH 
subpopulations isolated from MCF-10A Src-transformed cells. Canonical scores for the 
first two factors of fluorescence patterns were generated and plotted through Linear 




Figure 2.3. Correct unknown identification (CUI) of blinded cell mixture samples from 
the MCF-10A ER-Src system using either three FP or individual FP channel. Mixtures 
were in 0, 20, 50, 75 or 100% CSC. CUI was normalized to the percentage from the triple 
channel, which provides the highest identification accuracy.  
 
2.3.3 Development of a phenotypic plastic CSC model. Although the MCF-10A 
ER-Src system provides a way to enrich CSCs, it does not reflect their dynamic plasticity. 
For this reason, we developed a second model system to monitor the CSC plasticity using 
a diploid, non-tumorigenic cell line (S1 cells).33 These cells are highly differentiated and 
polarized. Expression of the Hippo transducer TAZ in these cells induced transformation, 
an EMT and the acquisition of stem cell properties (Figure 2.4A-C), consistent with 
previous findings.34,35 A consequence of TAZ transformation and the EMT was loss of the 
integrin α6β4, and this loss had a causal role in the genesis of CSCs. Re-expression of this 
integrin in TAZ-transformed cells reversed the EMT and resulted in loss of stem cell 
properties (Figure 2.4A-C). We termed these cells de-CSCs. The identity of non-CSCs, 
CSCs, and de-CSCs was further verified by morphology, relative expression of epithelial 




Figure 2.4. Workflow of generating reversible S1 model.  Expression of active TAZ (4SA-
TAZ) in S1 epithelial cells generated an EMT and CSCs. CSCs were induced to 
differentiate and lose stemness by overexpressing β4 integrin. (A) The morphology of each 
population generated was shown. (B) The expression of key EMT and epithelial genes was 
quantified by qPCR. Fold changes in mRNA level were shown in the table. (C) 
Immunoblots of the S1 system showing the change in epithelial (β4 integrin and E-
cadherin) and mesenchymal (N-cadherin) proteins. Tubulin loading control was shown in 
each blot. (D) Cell self-renewal ability of each population was evaluated by serial passage 
of mammosphere formation assay.  
 
2.3.4 Detection of phenotypical changes on CSCs. After establishing the S1 
system, each of these populations was incubated with the sensor for 30 minutes, fluorescent 
patterns were obtained and analyzed. Consistent discrimination between the CSC and non-
CSC groups was observed (Figure 2.5A). In addition, de-CSCs clustered closely and 
overlapped with non-CSCs on the LDA plot, which could be due to the fact that both groups 
lack stem cell phenotypes and share a similar morphology (Figure 2.4A). The nanosensor 
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was also able to detect different percentages of CSCs in the heterogeneous populations 
(Figure 2.5B). Cross-validation among 0%, 50% and 100% CSC mixtures showed 100% 
accurate classification. Complete correct unknown identification of the blinded cell 
mixtures was also achieved. To evaluate the performance of the LDA algorithm used, we 
employed the receiver operating characteristic (ROC) analysis on the S1 data set. As shown 
in Figure 2.5C, ROC results showed an area under the curve of 1.0, indicating a complete 
separation between CSC and non/de-CSC population.  
 
Figure 2.5. Discrimination of CSCs, non-CSCs and de-CSCs from S1 system using 
BenzNP-FP nanosensor. (A) A canonical score plot for the first two factors of fluorescence 
patterns was obtained with BenzNP-FP nanosensor against CSCs, non-CSCs, and de-CSCs 
from S1 cell lines. The scores were generated through LDA with 95% confidence ellipses 
(n = 8). (B) Similarly, a canonical score plot was derived for the classification of different 
ratios of CSC and non-CSC mixture. (C) Receiver operating characteristic analysis of 
CSCs, non-CSCs and de-CSCs from the S1 system. For analysis purpose, non-CSC and 
de-CSC were combined into one group and referred as non/de-CSC. The area under the 




2.3.5 Sensing of patient-derived xenografts. To determine the potential utility of 
our sensor in human tumors, we tested the sensing system on patient-derived xenografts 
(PDX). PDX tumors were generated by transplanting tumor specimens from an individual 
breast cancer patient into immuno-compromised NSG mice. CSCs (CD44high/CD24low) and 
non-CSCs (CD44low/CD24high) were isolated from PDX tumors by fluorescence-activated 
cell sorting (FACS) (Figure 2.6A). Both populations (CSC and non-CSC) were sorted at 
the same time using a two-way sort to minimize the sorting effect on cell surface 
alterations. The identity of each population was validated by assessing their self-renewal 
ability in mammosphere assays (Figure 2.6B). A similar sensing strategy was performed 
on PDX-derived CSCs and non-CSCs. The canonical score plot obtained showed complete 
separation of the two groups with 100% classification accuracy (Figure 2.6C). Unknown 
samples from each group were tested and correctly identified into either CSCs or non-CSCs 




Figure 2.6. Isolation, characterization, and discrimination of primary CSCs from patient-
derived xenografts. (A) CSCs and non-CSCs were isolated from PDX models of human 
breast cancer by FACS using CD44 and CD24 markers. (B) Self-renewal potential of these 
two populations was assessed by serial passage mammosphere formation assay. (C) CSC 
and non-CSCs from PDX were sensed with BzNP-FP nanosensor. Fluorescence patterns 
were analyzed through LDA. Canonical plot of the first two scores for CSC and Non-CSC 
samples was generated with 95% confidence ellipses. Unknown samples from each group 
were correctly identified based on the established training set. 
2.4 Discussion 
CSCs present crucial targets for breast cancer therapy.36,37 The plastic nature of 
CSCs as they respond to the environment has enriched our knowledge of the EMT and 
MET.10,11 Much information is harbored in the physical properties of cells, yet there are 
significant challenges in extracting that data in a quantitative and reliable way. In this 
paper, we use a nanosensor array as an alternative strategy to phenotype CSCs. The key in 
array-based sensing is being able to generate distinct patterns through selective interactions 
between sensor elements and analytes. To achieve this, the surface functionality of AuNPs 
is carefully considered in the sensor design.  Previously, we explored a library of AuNPs 
with different hydrophobicity, aromaticity, and hydrogen bonding characteristics. It was 
discovered that benzyl-terminated AuNP contributed significantly to the differential sensor 
responses with cells.25,26, 38  To ensure a high selectivity in profiling the overall 
physicochemical changes on cancer stem cells, we chose the Benzyl-NP as the interacting 
unit in this study. The successful discrimination between non-CSC and CSCs shows high 
accuracy of such sensing approach (Figure 2.2 & 2.5A). In the cell mixture studies for both 
MCF-10A ER-Src and S1 models, we observed that when CSCs were added to non-CSCs 
at a percentage as low as 25%, the sensor output was altered, demonstrating a high level of 
sensitivity of the nanosenor (Figure 2.2 & 2.5B). The reliability of our sensor strategy is 
further demonstrated in its ability to identify unknown samples. By computing the 
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Msahalanobis squared distance between the test samples and trained groups (CSCs and 
non-CSCs), unknown samples were clustered into the closest group. The high percentage 
of correct unknown identification validates the reliability of our sensor. Furthermore, all 
sensor elements were mixed in one well in the microplate, which reduces sensor material 
cost and analysis steps.  
Currently, the nature of the interactions between the nanosensor and cell surface is 
not well understood. The sensor must interact with different components of cell membranes 
in order to preferentially release quenched fluorescent proteins. Carefully examining sensor 
composition reveals that there are potentially two places where those interactions could 
occur. First, the cationic amine group on the sensor could electrostatically bind with 
portions of cell membranes containing anionic groups, such as lipids and proteins.39 In 
addition, the benzyl head group is likely to form pi-pi stacking interaction with other 
aromatic structures in the cell membrane, such as proteins containing tyrosine and 
tryptophan residues.40 Since cell surface composition varies significantly among cell types 
and states,41,42 the differential fluorescence responses of CSCs, non-CSCs, and de-CSCs 
observed here are likely due to a mixture of changes in the cell surface functionalities. Our 
previous study showed that the sensor system was highly sensitive to glycosylation 
patterns, providing a possible origin for the responses observed in the current study.43 
Further mechanistic studies are needed to enrich our current understanding.  
Poorly differentiated tumors such as triple negative breast cancer exhibit an 
embryonic gene expression pattern 44 and are dependent upon developmental signaling 
pathways. 45 -, 46 , 47  These pathways play crucial roles initiating and maintaining the 
pluripotency of CSCs,48, 49 in particular the Hippo pathway because the Hippo transducer 
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TAZ has a causal role in sustaining CSC function.34,50 Our data on TAZ-mediated genesis 
of CSCs revealed that a key integrin, α6β4, has an important role in impeding the CSC 
phenotype.  The restoration of α6β4 reverted stem cell properties (Figure 2.4).  The results 
demonstrate that the S1 system has the advantage of generating CSCs from breast epithelial 
cells and being able to reverse stemness by expressing a single integrin. The reversible S1 
system reflected the dynamic state of CSCs and the sensing results showed that the 
nanosensor can capture such phenotypic changes by clustering them into different groups. 
Taken together, the data obtained using two different in vitro models demonstrate the 
power of array-based sensing in profiling CSCs. 
There has been intense interest in personalized cancer medicine based on the fact 
that the geno- and phenotypic properties of tumors differ significantly among patients.  
Interestingly, recent data revealed that CSCs isolated from patients with same cancer 
(colon) differ in their properties and response to chemotherapeutics.14 This observation 
highlights the need to profile CSCs from individual breast cancer patients. In our study, a 
clear discrimination of CSCs in PDX models of human breast cancer was observed in 
Figure 2.6. This result is exciting because it opens the possibility of phenotyping CSCs 
from individual patients, though further refinement of individual samples is needed due to 
tumor heterogeneity. The system presents a promising future of monitoring each patient’s 
CSCs responses to different chemotherapeutics, which could be a potential new dimension 
for precision medicine. 
2.5 Conclusion 
In summary, we report a nanoparticle-fluorescent-protein based multi-channel 
sensor that rapidly discriminates CSC from non-CSC phenotypes. This sensor platform 
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provides a tool with applications in both diagnostics and screening approaches for 
therapeutic design. The nanosensor is highly versatile, as demonstrated by rapid detection 
of CSCs in both in vitro and in vivo models. Taken together, the ability to rapidly identify 
and profile CSCs provides access to new strategies to combat the multidrug resistance, 
tumor recurrence and metastasis associated with CSCs. 
2.6 Experimental Section 
2.6.1 Nanoparticle Synthesis and Characterization. Benzyl gold nanoparticles 
with a core diameter of 2nm were synthesized according to previous reports.51 Detailed 
synthesis scheme and characterization of BenzNPs can be found in the supplementary 
information. The characterization data corresponds well with that reported in the literature.  
2.6.2 Fluorescent Proteins Expression. EGFP, EBFP, tdTomato 52  were 
synthesized and characterized following previously reported procedures. In brief, 
Escherichia coli BL21 (DE3) strain was transformed with plasmids containing recombinant 
proteins. Fluorescent proteins were then purified by Co2+ nitrilotriacetate columns and 
characterized by SDS-PAGE gel, absorbance and fluorescence spectra. The 
characterization data is similar with previous published work.27  
2.6.3 Isolation of Mammary Epithelial Cells. MCF-10A cells that express a 
tamoxifen-inducible ER-SRC were provided by Dr. Kevin Struhl (Harvard Medical 
School, Boston, MA).  Protocols for the isolation of the CD44high/CD24low population from 
these Src-transformed MCF10A cells and characterization of distinct EPTH and MES sub-
populations within the CD44high/CD24low population based on the expression of the β6 
integrin have been described.32 
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2.6.4 Engineering S1 Cell Lines. HMT-3522 S1 human mammary epithelial cells 
were obtained from Dr. Mina Bissell 53 (Lawrence Berkeley National Laboratory) and 
maintained as described by the Bissell laboratory.54 These cells were transfected with either 
empty vector (pLVX-puro) or a constitutively active form of TAZ that contains the 
following S to A point mutations (S66A, S89A, S117A and S311A) and is referred to as 
4SA-TAZ (pLVX-4SA-TAZ; provided by Xaralabos Varelas, Boston University).55 Stable 
transfectants were selected using 2 ug/ml puromycin. To induce differentiation of S1 cells 
expressing 4SA-TAZ, these cells were transfected with a β4 integrin plasmid (pRC-β4) and 
selected with neomycin. All cell populations used were stable cell lines, which were 
cultured for two passages without any antibiotics to avoid potential problems related to 
transfection- or selection-related surface alterations.  All cell populations were assessed for 
self-renewal ability using serial mammosphere assay as described previously. 56  The 
expression of key stem cell and EMT genes was quantified by qPCR. 
2.6.5 Patient-derived Xenografts (PDX). PDX models of human triple-negative 
breast cancer were maintained in immunocompromised NOD.Cg-Prkdcscid IL2rgtm1Wjl 
(abbreviated as NSG) mice as described previously.50 Tumors were harvested, minced and 
digested for 2-3 hours at 37°C with a mixture of collagenase (Roche, Indianapolis, IN, 
USA) and hyaluronidase (MP Biomedicals, Solon, OH, USA). The digested cells were 
passed through a cell strainer to obtain single cell suspensions and plated briefly in serum 
(1–2 h) to deplete mammary fibroblasts. To isolate CSCs from PDX tumors, dissociated 
cells were stained with antibodies for lineage markers (CD31, CD45, Ter-119), CD44 and 
CD24. The lineage antibodies were purchased from eBioscience. The various populations 
were sorted using flow cytometry [(nozzle size (mm)/pressure (psi): 85/45)]. Both 
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populations (CSC and non-CSC) were sorted at the same time using two-way sort to 
minimize the sorting effect on cell surface alterations. 
2.6.6 Immunoblotting and qPCR. Cells were extracted using a Triton X-100 
buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1 mM 
phenylmethanesulfonylfluoride [PMSF] and protease inhibitors), and proteins were 
separated by SDS-PAGE under reducing conditions.  These gels were immunoblotted 
using the following Abs: N-Cadherin (Invitrogen); E-Cadherin (Invitrogen); β4 integrin 
505; 57  c-myc (Cell Signaling); actin (Sigma); FLAG (Sigma). For qPCR, RNA was 
isolated using the NucleopSpin RNA kit (Macherey-Nagel) and 1 ug of total RNA was 
used to make cDNAs using a cDNA synthesis kit (Biorad). qPCR was performed using a 
SYBR green (Applied Biosystems) master mix as described by the manufacturer. qPCR 
primers were designed using primer bank.58 
2.6.7 Cell Culture.  MCF10A-ER-Src cells were cultured in DMEM/F12 medium 
containing 5% horse serum and other growth factors as described previously.59 S1 cell lines 
were grown and maintained as described by the Bissell laboratory.54 All cells were 
maintained at 37 °C in a humidified atmosphere containing 5% CO2. Cells were regularly 
passaged by trypsinization with 0.25% trypsin with EDTA, (Invitrogen) in PBS (pH 7.2). 
At ~80% confluence, cells were trypsinized and plated in 96-well plates (Greiner black-
and-clear bottom) and cultured for 24 hrs. Cells were washed once with PBS buffer before 
proceeding to the sensing studies. 
2.6.8 Sensing Studies. The sensor was prepared by mixing 100nM of BenzNP with 
equimolar (100nM) of EBFP, EGFP and tdTomato in 5mM sodium phosphate buffer 
(pH7.4) for 30 minutes at room temperature. Then, 200uL of sensor solution was incubated 
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with and without the cell populations (washed once with PBS) in 96-well microplates for 
30 minutes. The change of fluorescence intensity in each channel was recorded at its 
respective wavelength (EBFP: 380/450nm, EGFP: 475/510nm, tdTomato: 550/585nm) on 
a Molecular Devices SpectraMax M2 microplate reader using appropriate filters.  
2.6.9 Linear Discriminant Analysis. The raw fluorescence data was processed by 
classical linear discriminant analysis using SYSTAT software (version 11.0, 
SystatSoftware, Richmond, CA, USA). In LDA, all variables were used in the model 
(complete mode) and the tolerance was set as 0.001. The raw fluorescence response 
patterns were transformed to canonical patterns where the ratio of between-class variance 
to the within-class variance was maximized according to the preassigned grouping. To 
identify the unknown samples, the fluorescence response patterns of each new case was 
first converted to canonical scores using the discriminant functions established on the 
training cases. Then, Mahalanobis distance60 was computed. Blinded cases were predicted 
to belong to the closest group, defined by the shortest Mahalanobis distance.  
2.6.10 Receiver Operating Characteristic Analysis. Receiver operating 
characteristic (ROC) analysis was used to evaluate the performacne of LDA algorithm. 
ROC analysis  calcualtes the true and fales postive rate of a given binary sample set. By 
ploting the two rates, an area under the curve can be derived, which indicates the ability of 
the test to discriminate the desired two populations. ROC analysis was done using Rstudio 
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DIFFERENTIATION OF CANCER STEM CELLS THROUGH 
NANOPARTICLE SURFACE ENGINEERING 
3.1 Abstract 
Cancer stem cells (CSCs) are a crucial therapeutic target because of their role in 
resistance to chemo- and radiation therapy, metastasis, and tumor recurrence. 
Differentiation therapy presents a potential strategy for ‘defanging’ CSCs. To date, only a 
limited number of small molecule and nanomaterial-based differentiating agents have been 
identified. We report here the integrated use of nanoparticle engineering and hypothesis-
free sensing to identify nanoparticles capable of efficient differentiation of CSCs into novel 
non-CSC phenotypes. Using this strategy, we identified a nanoparticle that induces CSC 
differentiation by increasing intracellular reactive oxygen species levels. Importantly, this 
novel phenotype is more susceptible to drug treatment than either CSCs or non-CSCs, 
demonstrating a potentially powerful strategy for anticancer therapeutics. 
3.2 Introduction 
The majority of solid tumors harbor a population of cells with stem cell 
characteristics, including the ability to self-renew, differentiate and populate new tumors.1 
These cells are referred to as cancer stem cells (CSCs). CSCs are resistant to standard 
chemotherapy and are considered responsible for tumor recurrence and metastasis, making 
them key therapeutic targets. 2 , 3  One key characteristic of CSCs is their phenotypic 
plasticity. Through epithelial-to-mesenchymal transition (EMT), cancer cells can gain stem 
cell properties to become more aggressive. 4  Conversely, CSCs can also differentiate, 
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undergoing mesenchymal-to-epithelial transition (MET), a process that may facilitate 
metastasis.5,6 The CSC dynamic is further complicated by the emerging evidence of partial 
EMT, where the intermediate states express both epithelial and mesenchymal traits.4,7,8 
Given that the EMT can promote the acquisition of stem cell properties,4, 9 
therapeutic agents that promote differentiation should diminish the frequency of CSCs, 
rendering tumors less aggressive and more responsive to conventional therapy. This 
approach is known as differentiation therapy and has considerable therapeutic potential.10 
One of the most successful examples of differentiation therapy is the use of all-trans 
retinoic acid in acute promyelocytic leukemia (APL). By promoting cells blocked at a 
distinct cellular maturation stage to differentiate, APL patients who received such 
treatment in combination with other chemotherapies have an overall cure rate exceeding 
80%.11-, 12, 13   
There has been a widespread interest in identifying molecules that selectively kill 
CSCs or promote their differentiation.14 In 2009, Gupta et al. screened 16,000 compounds 
and found that ~only 0.2% of these compounds showed selective toxicity for breast 
CSCs.15 Another screen conducted in 2012 revealed a dopamine receptor antagonist as a 
potent molecule that selectively targets CSCs.16 In addition to small molecules, nanoscale 
materials have gained significant interest as therapeutic agents for several applications, 
including drug delivery, immunoregulation, and bio-orthogonal drug activation.17-,18,19,20 
Recent studies have shown that nanomaterials can either kill or alter the phenotype of 
CSCs. For instance, carbon materials such as metallofullerenes21 and graphene oxide22 can 
induce CSC differentiation in vitro. Since hydrophobicity plays crucial rules in normal 
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stem cell biology, 23,24 it is likely that the highly hydrophobic nature of these nanomaterials 
is responsible for differentiating CSCs. 
Despite the progress in identifying novel differentiation therapeutics, the discovery 
process is slow and difficult. Two major challenges are present in the generation of 
nanoparticle-based therapeutics. First, most studies use hypothesis-driven approaches for 
CSC differentiation screening that involve the use of specific markers. Since CSCs are 
highly plastic25,26 and associated with different EMT states,7,8 utilizing one or two specific 
markers will likely obscure the detection of differentiated phenotypes. More significantly, 
hypothesis-driven strategies limit detection to a pre-defined phenotype, potentially failing 
to detect other differentiated phenotypes. In addition, commonly used techniques such as 
RT-PCR, flow cytometry and mammospheres formation assay, require special 
instrumentation and multi-step processing of cells, limiting their compatibility with a high-
throughput platform.27-,28,29  
A second limitation in developing nanotherapeutics for CSC differentiation is the 
challenge of controlling surface properties inherent to many nanomaterial platforms.30,31 
These properties are crucial, determining the therapeutic efficacy of these nanomaterials, 
as well as impacting parameters including pharmacokinetics and biodistribution.32  
Taken together limitations in screening and platform design space have hindered 
the exploration of nanomaterial-based CSC differentiation, and as such, there is a clear 
need for a method that features greater control over chemical diversity and can 
simultaneously increase throughput. 
Gold nanoparticles (AuNPs) feature facile surface functionalization, 33 
biologically-favorable size, and tunable contact area.34,35 The gold used for the core is also 
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essentially non-toxic.36 These properties have led to their utilization for applications as 
diverse as drug delivery,37 antifouling materials,38 and sensing in complex matrices.39 As 
such, they are also particularly promising candidates for screening CSC differentiation 
inducers.  
 
Figure 3.1. Schematic illustration of the integration of nanoparticle design and hypothesis-
free sensing. Chemical structure of the 2-nm core diameter AuNPs used to stimulate CSCs 
are shown on the left. After AuNP treatment, cells were washed and incubated with the 
nanosensor to rapidly collect phenotypic information. The novel phenotype identified 
through the sensing screen was further subject to drug treatment to see if it was more 
sensitive to chemotherapy. 
 
We report here an integrated screening/synthetic strategy for generating 
nanomaterial therapeutics for CSC differentiation (Figure 3.1). This approach uses the 
precise level of structural control afforded by AuNPs to systematically investigate the 
effects of NP surface chemistry on CSC differentiation. This therapeutic design capability 
is complemented by a hypothesis-free, array-based sensing platform for CSC screening. 
As opposed to the traditional biomarker-based approach, this array-based sensing uses a 
signature-based method to profile an entire matrix of bioanalytes, 40  effectively 
circumventing the bottleneck of receptor specificity as demonstrated through 
discrimination of CSCs from non-CSCs.41  
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In the work reported herein, a population of breast cancer cells enriched for a 
mesenchymal phenotype and stem cell properties was treated with cationic AuNPs capable 
of readily entering cells. 42   These particles bore headgroups with highly controlled 
hydrophobicity ranging from hydrophilic (TTMA) to highly hydrophobic (C10). 43 
Screening was then performed using hypothesis-free sensing. By reading off the 
fluorescence patterns generated through sensor-cell interactions, we discovered that one 
particle (C6NP) robustly promoted CSC differentiation. Further evaluation revealed that 
C6NP promoted a MET, decreasing expression of key stem cell genes and mesenchymal 
markers. Mechanistic studies showed that this differentiation is associated with an increase 
in reactive oxygen species (ROS). Importantly, when CSCs were treated with C6NP in 
combination with mitochondrial inhibitors, a selective synergistic killing of CSCs was 
achieved, demonstrating the capability of this differentiation strategy for addressing CSC 
drug resistance (Figure 3.1).  
3.3 Results and Discussion  
3.3.1 AuNPs with tunable surface functionality for structure-activity studies. 
We first synthesized and characterized a library of five different AuNPs 44,45  to explore 
the structure- activity relationship of AuNPs on CSC differentiation. The monolayer of the 
nanoparticle features a hydrophobic alkane chain, which provides stability in a 
biologically-relevant environment,46,47 followed by a tetra(ethylene glycol) moiety  that 
offers biocompatibility and helps to expose the terminal head-groups on the NP surface, 
allowing us to study the direct effects of surface chemistry on CSC differentiation. Since 
hydrophobicity has key implications in stem cell biology, including cell adhesion, 
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migration and differentiation,23,24 we chose five functional AuNP head groups with 
parametrically varying degrees of hydrophobicity (Figure 3.1). 
 
Figure 3.2. Characterization of HMLER subpopulations. (A) Morphology of HMLER 
CD24high/β4high and CD24low/β4low imaged under phase contrast microscopy at 10x 
magnification. (B) HMLER cells contain distinct populations of CD44high/CD24low (CSCs) 
and CD44low/CD24high (non-CSCs). (C) HMLER cells sorted based the CD24 and β4 
integrin expression into CSCs and NCSCs sub-populations. (D) HMLER CD24high/β4high 
and CD24low/β4low cells were serial passaged in a mammosphere assay. CD24low/β4low 
showed significantly more self-renewal ability than CD24high/β4high over three passages. P-
values for CSC population at P2 and P3 are 0.003 and 0.002, respectively. 
 
3.3.2 Identification of two sub-populations of transformed mammary 
epithelial cells that differ in CSC properties. We made use of human mammary 
epithelial cells (HMECs) that were transformed by SV40 large-T antigen, the telomerase 
catalytic subunit, and H-Ras. These modified HMECs are referred to as HMLER cells.29 
Using established markers for breast CSCs (CD44 and CD24), HMLERs were sorted into 
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CD44high/CD24low (CSC) and CD44low/CD24high (non-CSC) populations (Figure 3.2A).  
We were also able to further sort them based on the expression of CD24 and β4 integrin to 
generate two sub-populations with distinct morphological differences: HMLER 
CD24low/β4low cells are fibroblastic, mesenchymal like with a spindle-shape morphology, 
whereas the HMLER CD24high/β4high population is more epithelial (Figure 3.2B-C). We 
assessed the self-renewal potential of these populations by serial mammosphere formation. 
The results showed that CD24low/β4low cells had the ability to self-renew over several 
passages, while the CD24high/β4high cells gradually lost their ability to form mammospheres 
(Figure 3.2D).  Based on their morphology and self-renewal potential, we termed the 
HMLER CD24low/β4low cells and CD24high/β4high as CSCs and non-CSCs (NCSCs), 
respectively, for the following studies.  These findings support our previous conclusion 
that the expression of the β4 integrin is low in breast CSCs.48 
Sensor array design. The nanosensor employed in this work is comprised of a 
cationic gold nanoparticle (2nm core in diameter) bearing a benzyl terminal group 
(BenzNP) and three types of fluorescent proteins (FPs).41 The nanosensor was formed by 
mixing equimolar of BenzNP with FPs. Due to electrostatic interactions, FPs were drawn 
in close proximity to the gold core and their fluorescence was quenched through energy 
transfer to BenzNP, resulting in a ‘sensor-off’ state. Upon addition of cells, cell surface 
functionalities compete with FPs for AuNP binding and simultaneously release FPs into 
solution, freely emitting light. As a result, the sensor is turned on and fluorescence signals 
can be collected as the signature for the target analyte. Our hypothesis is that the cell 
surface composition of CSCs will be altered under nanoparticle treatment, which will be 
captured by the nanosensor with a unique fluorescent pattern (Figure 3.3). This type of 
 
 47 
“turn-on” sensor has successfully been employed in discriminating a range of bioanalytes 
including bacteria,49 mammalian cells,50 and patient sera.51 
 
Figure 3.3. Schematic illustration of sensor composition and selective interactions with 
cell surfaces.  
 
 3.3.3 Screening for NP-induced CSC differentiation. The screen of the small 
NP library began with treating CSCs with individual AuNPs at a non-toxic concentration 
(Figure 3.4) for 72 hrs to allow potential differentiation effects to occur.  Since the tested 
NPs are only 2 nm in diameter and carry positive charges, they should rapidly cross the 
cell membrane. Consistent with our previous work,52 we observed intracellular uptake of 





Figure 3.4. Cytotoxicity of tested NPs on HMLER-CSCs. Each NP was treated at 100 nM 
for 72hrs.  Three biological replicates were used for each treatment group. Viability was 
normalized to the cell only group. 
 
At the end of NP treatment, cells were washed with phosphate-buffered saline 
(PBS) to remove excess NPs, followed by a 30 min incubation with the nanosensor. The 
fluorescence signals of the sensor were immediately measured, and the fluorescent patterns 
were analyzed using linear discriminant analysis (LDA). Overall, the results can be 
obtained in less than an hour after sensor incubation, which is much more efficient than 
other screening assays. Since the cell surface composition varies significantly among cell 
types and states,53,54 the resulting fluorescent pattern is unique for CSCs under each NP 
treatment (Figure 3.5A). LDA plot revealed that CSCs and NCSCs were well discriminated 
from each other. NP treatment resulted in a range of different effects on CSCs with some 
NPs closer to the control group (e.g. TTMA, C2 and C10) and others separated out (e.g. 
C4 and C6) (Figure 3.5B). Interestingly, none of the treatment groups overlapped with 
NCSCs, suggesting that NPs did not revert CSCs to NCSC state, rather new phenotypes 
were achieved. Since our sensor is highly sensitive to cell surface glycosylation,55 it is 
likely that NP treatment alters glycosylation patterns and that these alterations contribute 





Figure 3.5. Sensing screen in capturing phenotypic changes of CSCs under different AuNP 
treatment. (A) Fluorescent responses of CSCs (isolated from HMLER model) under 
different AuNP treatment. Normalized fluorescence intensities against sensor only were 
obtained after 30 min of sensor incubation with cells (n=8). C: TTMA means CSCs treated 
with TTMA. (B) Fluorescence patterns obtained were analyzed through LDA. Canonical 
plot of the first two scores was generated with 95% confidence ellipses (n=8). 
 
Next, we quantified the pairwise distance between each tested group to determine 
which NP treatment had the most substantial effect on CSCs. The F-index was calculated 
based on the within-class variance as well as between-class variance. Larger values of F-
index indicated better separation or more difference between the two groups.56,57 As shown 
in Table 3.1, when NP treated groups were compared with either non-treated CSCs or 
NCSCs, C6NP was the furthest from both control CSCs and control NCSCs with an F-
index of 32.7 and 147.8 (respectively), indicating a promising hit from the sensing screen 
has been identified. The generality of this method was further validated on a different and 
more stringent CSC model system: MCF10A-ER-Src.48 The sensing trend also suggested 



















0       
CSC: C2 1.9 0      
CSC: C4 8.2 17.0 0     
CSC: C6 16.9 29.1 1.6 0    
CSC: C10 2.9 2.4 12.3 21.9 0   
CSC only 13.6 17.2 24.3 32.7 19.9 0  
NCSC only 91.6 74.2 124.9 147.8 77.3 161.3 0 
a Sensing results were used to compute F-index of each pair in SYSTAT software. Larger 




Figure 3.6. Sensing screen in capturing phenotypic changes of CSCs (from MCF10A-ER-
Src system) under different AuNP treatment. (A) Normalized fluorescence intensities 
against sensor only group. (B) LDA canonical plot of the first two scores was generated 




3.3.4 Identifying phenotypic alterations from C6NP treatment. Based on the 
strong difference in cell nanosensor response for C6NP, we performed phenotypic and 
mechanistic studies on the cells. In response to C6NP treatment, we observed that cells lost 
their mesenchymal, spindle shape and became more epithelial in morphology. The mRNA 
levels of key stem cell genes (Oct4 and Zeb 1) and mesenchymal markers (CDH2 and 
fibronectin) were significantly reduced, while epithelial differentiation related genes 
(CD24, integrin β4, and α6A) were increased (Figure 3.7A), suggesting a MET had 
occurred. The phenotypic alterations were further evident in the decreased protein 
expression level of Zeb 1 and N-cadherin (Figure 3.7B). Furthermore, C6NP diminished 
CSC properties as evidenced by a decrease in mammosphere formation (Figure 3.7C). We 
also observed a significant decrease in the ability of C6NP-treated cells to adhere to laminin 
511, which we have reported is a preferred extracellular matrix for CSCs (Figure 3.7D).58  
These data demonstrate that C6NP impacts CSC properties. Taken together, these data 
demonstrate that C6NP promotes epithelial differentiation and loss of CSC properties.  
Figure 3.7. MET evaluation of HMLER-CSCs treated with 100 nM C6NP for 72 hrs. (A) 
mRNA quantification of key stem (Oct4 and Zeb 1), mesenchymal (CDH2 and 
Fibronectin) and epithelial differentiation related genes (CD24, integrin β4, and α6A) in 
response to C6NP treatment using qRT-PCR. Fold changes in mRNA level were 
normalized to GAPDH and compared with no particle treated control. (B) Immunoblot of 
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mesenchymal (N-cadherin) and stem cell marker (Zeb 1) expression level of CSCs under 
C6NP treatment. Actin is used as a loading control. (C) Significant reduction in 
mammosphere formation ability in C6NP treated CSCs was observed.  (D) C6NP treated 
CSCs show decreased adhesion to laminin 511, a preferred CSC substrate (p-value of 
0.016). Laminin 111 is used as a control substrate. Statistical significance was determined 
by two-tailed student t-test. *= p < 0.05, **= p < 0.01, ***= p < 0.001. 
 
3.3.5 Increased ROS levels are a consequence of C6NP treatment.  Based on 
the observation that CSCs have a lower level of intracellular reactive oxygen species (ROS) 
than their non-tumorigenic cell partners, 59,60 we investigated whether C6NP treatment 
impacted ROS levels. Exposure of CSCs with C6NP resulted in a significant increase in 
ROS (Figure 3.8).  When the ROS scavenger N-acetyl-L-cysteine (NAC) was applied in 
combination with C6NP, ROS levels were reduced, demonstrating that C6NP increases 
ROS in CSCs. Although other NPs induced an initial burst of ROS at 30 minutes, only the 
C6NP was able to sustain this burst for 4 hrs (Figure 3.9).  The initial burst of ROS is likely 
induced by the nature of nanoparticles61 and elevated oxidative stress could activate the 
innate cellular defense mechanism to clear out foreign particles.62  
 
Figure 3.8. ROS production of CSCs and NCSCs treated with C6NP. The ROS level in 
each treatment group was normalized to its respective cell only control group (NCSCs and 
CSCs). Only CSCs treated with C6NP showed an increase in ROS level as compared to its 






Figure 3.9. ROS production of CSCs treated with different types of NPs for either 30 min 
(blue) or 4 hrs (orange). All other NPs induced increased ROS production relative to the 
cell only control, however substantially higher levels of ROS were observed with C6, in 
particular after 4 hrs incubation. 
 
We next sought to understand how the sustained induction of ROS by the C6NP 
could promote CSC differentiation. Our hypothesis is based on our previous work on the 
importance of mRNA splicing in controlling the expression of key genes that promote a 
CSC phenotype,48,63 most notably, the α6β1 integrin. There are two splice variants of the 
a6 integrin subunit (α6A and α6B). Previous studies demonstrated that the α6Bβ1 integrin 
promotes a CSC phenotype while α6Aβ1 promotes a more differentiated, non-CSC 
phenotype.48 Based on these data, we observed that C6NP induced expression of the α6A 
splice variant.  Importantly, this induction of α6A is ROS-dependent, supporting an ROS-




Figure 3.10. mRNA quantification of α6A splicing gene when CSCs were treated with 100 
nM C6NP with or without ROS inhibitor NAC. Fold changes in mRNA level were 
normalized to GAPDH and compared with cell only control. Statistical significance was 
determined by two-tailed student t-test. *= p < 0.05, **= p < 0.01, ***= p < 0.001. 
 
Normal stem cells produce a lower amount of ROS in order to maintain their 
quiescent state and self-renewal capabilities.64 During differentiation, cells can adjust their 
metabolic system to generate enough energy for this cellular process. Evidence has shown 
that increased ROS levels can promote the differentiation of embryonic stem cells.65-,66,67 
This finding is consistent with our results that implicate ROS in an mRNA splicing 
program that promotes epithelial differentiation. 
The ability of C6NP to promote the epithelial differentiation of CSCs was further 
investigated in a patient-derived xenograft, where CSCs and NCSCs were isolated using 
CD24 and CD44 markers. As evident in Figure 3.11A, CSCs under C6NP treatment 
showed a diminished ability to form mammospheres. An increase of ROS was also 
observed in CSCs treated with C6NP (Figure 3.11B). This data shows promising 
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generalization of our nanoparticle approach, and the integration of AuNPs-based 
hypothesis-free sensing and functional NP design could be applied in clinically relevant 
settings.  
 
Figure 3.11. Validation of C6NP on CSCs and NCSCs isolated from a patient-derived 
xenograft using CD24 and CD44 markers. (A) Mammosphere formation assay of CSCs 
under 100 nM C6NP treatment for 48 hrs. (B) ROS production of CSCs and CSCs un-der 
100 nM C6NP treatment. Fluorescence fold change of each treatment group was 
normalized to its respective cell only control group (NCSCs and CSCs). Only CSCs show 
an increase in ROS levels (p value of 0.00016) upon receiving C6NP treatment. 
 
3.3.6 Sensitization of CSCs for drug treatment.  Direct elimination of CSCs as a 
therapeutic approach is challenged by the chemo- and radiation resistant nature of these 
cells.68 In contrast, differentiation therapy aims to induce CSCs to a less aggressive state, 
consequentially becoming more susceptible to existing therapies. To evaluate whether 
epithelial differentiation caused by C6NP has any therapeutic relevance, we assessed the 
efficacy of a metabolic inhibitor, 2-deoxy-D-glucose (2DG) on CSCs, either alone or in 
combination with C6NP. Indeed, a non-toxic dose (100 nM) of C6NP significantly 
potentiated the ability of 2DG to kill CSCs (Figure 3.12A). Furthermore, the combination 
index (CI) was calculated to quantitatively determine if the cotreatment of C6NP and 2DG 
had any synergistic effects on CSCs. CI < 1 indicates synergism, while CI = 1 indicates 
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additivity, and CI > 1 indicates antagonism.69 Surprisingly, synergy was observed at all 
tested combinations with CI values ranging from 0.66 to 0.25 (Table 3.2). Interestingly, 
when tested against NCSCs, no significant change in cell death was seen at the dosages 
where synergistic elimination of CSCs was observed, suggesting the synergistic killing was 
specific to CSCs (Figure 3.12B). This finding not only supports the idea of differentiation 
therapy in solid tumors, but also opens the potential therapeutic applications of 
nanomaterials in combating CSCs. 
 
Figure 3.12. IC50 of 2DG alone or in combination with C6NP on HMLER-CSCs (A) or 
NCSCs (B). CSCs or NCSCs were treated with either 2DG or in combination of 100 nM 
C6NP for 48 hrs. Cells viability was normalized to cell only group without any treatment 
(n=3). 100 nM C6NP is circled to indicate the non-toxic dosage of C6NP used.  
 
Table 3.2. Quantification of synergy for combination therapy on HMLER-CSCs.  
 
[C6NP] in mM [2DG] in mM Killing Effect Combination Index (CI) 
10-4 0.25 0.31 0.66 
10-4 2.5 0.52 0.46 
10-4 5 0.57 0.45 
10-4 10 0.68 0.35 
10-4 20 0.73 0.32 
10-4 40 0.76 0.33 
10-4 80 0.83 0.25 
10-4 100 0.84 0.25 
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3.4 Conclusion  
In summary, we report the dual use of AuNPs as therapeutics and as sensors for 
effecting CSCs differentiation.  The precise level of control afforded over nanoparticle 
structure allows us to systematically investigate the effects of surface chemistry on CSC 
differentiation. Through coupling with the nanosensor platform, the resulting cell 
phenotype can be accessed in a matter of minutes, a feature highly desirable for high-
throughput and high-content screening. By combining NP engineering and hypothesis-free 
sensing, we successfully identified a novel phenotype that is more susceptible to traditional 
chemotherapeutic treatment. The resulting cells presented an increased level of ROS which 
could be responsible for sensitizing CSCs to drug treatment. Overall, this work 
comprehensively demonstrates the application of functionalized AuNPs in multiple aspects 
of screening nanomaterials for CSC differentiation, with significant potential in addressing 
a key issue in cancer therapy. 
3.5 Experimental Section  
3.5.1 Nanoparticle Synthesis and Characterization. Gold nanoparticles with a 
core diameter of 2 nm and ligands were synthesized according to previous reports.70 In 
brief, 2 nm AuNPs were synthesized by Brust-Schiffrin two-phase method to obtain 
pentanethiol covered gold core. Functionalized AuNPs were synthesized through ligand 
exchange reactions in nitrogen atmosphere followed by multiple washing and dialysis.42 
Detailed characterization can be found in the supporting information. 
3.5.2 Fluorescent Protein Expression. EGFP, EBFP, and tdTomato were 
synthesized and characterized according to reported protocols.71 In short, Escherichia coli 
strain BL21 was transformed with plasmids containing corresponding recombinant 
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proteins. After growth in 2X YT media and induction, cells were lysed and purified by 
Co2+ nitrilotriacetate columns. Fluorescent proteins were further characterized by 12% 
SDS-PAGE gel, scanning absorbance and emission spectrum. The results are consistent 
with previously reported work.37  
3.5.3 Nanoparticle Treatment. CSCs and NCSCs were seeded at a density of 104 
cells per well on a 96-well microplate for overnight attachment. Before treatment, cells 
were washed once with phosphate-buffered saline (PBS). 150 µL of media containing 100 
nM of each NP were added to cells. After 72 hrs treatment, cells were washed once with 
PBS before proceeding to sensing studies.  
3.5.4 Sensing Studies. Nanosensor was formed by mixing equal molar of BenzNP 
and FPs (100 nM) in 5mM phosphate buffer for 30 min in dark at room temperature. After 
sensor was formed, 150 µL of sensor solution was incubated with or without cells in a 96-
well plate. The plate was kept in the dark. Fluorescent reading was recorded every 15 min 
until 45 min, using a SpectraMax M2 plate reader (Molecular Devices, San Jose, CA). The 
excitation/emission wavelength for each channel is the following: EBFP: 380/450 nm, 
EGFP: 475/510 nm, tdTomato:550/585 nm.  
3.5.5 Linear Discriminant Analysis. Linear discriminant analysis (LDA) was 
applied on raw fluorescence data to statistically classify each group, using SYSTAT 
software (version 11.0, Systat Software, Richmond, CA, U.S.A.). All variables were used 
in the complete mode and the tolerance was set as 0.001. Input data was transformed to 
canonical scores to best separate each group where the between-class variance was 
maximized while the within-class variance was minimized. To quantify how different each 
nanoparticle treatment group is from the control, the F-index was computed in SYSTAT. 
 
 59 
Larger values of F-index indicate smaller within-class variance and better between-class 
separation.56  
3.5.6 Cell Culture. HMLER cells were prepared by transforming human mammary 
epithelial cells (HMECs) with SV40 large-T antigen, the telomerase catalytic subunit, and 
H-Ras and kindly provided by Dr. Weinberg.29 HMLER cells were stained for integrin β4 
and CD24. Cells were then sorted into CD24low/β4low and CD24high/β4high. CD24 antibody 
was obtained from Biolegend (catalog 311104), β4 antibody was provided by the Dr Rita 
Falcioni.72 HMLER, HMLER CD24low/β4low, and HMLER CD24high/β4high were cultured 
in mammary epithelial cell growth basal medium with BPE, hEGF, Insulin, 
Hydrocortisone, and GA-1000 (components bought in a kit, Lonza, cc-3150).  
3.5.7 Inductively Coupled Plasma Mass Spectrometry (ICP-MS). For ICP-MS 
experiments, CSCs isolated from HMLER system were seeded in 48-well plate and treated 
with 100 nM NPs for 3 days. At the end of the treatment, cell supernatant was collected 
and attached cells were washed twice with PBS before subjecting to lysis buffer (Genlantis) 
for 30 min. Cells were then transferred into a 15-mL tube and digested with 0.5 mL of aqua 
regia for 24 hrs, and the sample was then diluted to 10 mL using de-ionized water. Au 
standard solutions (Perkin Elmer) were prepared prior to each experiment. A Perkin Elmer 
NEXION 300X ICP mass spectrometer was used for the analysis of samples. Prior to the 
analysis, daily performance measurements were done to ensure the instrument was 
operating under optimum conditions. Using the standard mode, 197Au signals were 
obtained. The RF power for the ICP was 1.6 kW, and the nebulizer gas flow rate was within 
a range of 0.9–1 L/min. The plasma gas flow rate and auxiliary gas flow rate were 16.5 
L/min and 1.4 L/min, respectively. The analog stage voltage and pulse stage for the detector 
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were −1600 V and 950 V, respectively. The deflector voltage was set to −12 V, and 50 ms 
was selected for the dwell time during the operation of the ICP-MS. 
 
Figure 3.13. Intracellular uptake of AuNPs on HMLER-CSC quantified by ICP-MS. Three 
biological replicates were used for each treatment group. Gold amount was normalized to 
a standard calibration curve. Statistical significance was determined by two-tailed student 
t-test. *= p < 0.05, **= p < 0.01, ***= p < 0.001. 
 
3.5.8 Mammosphere Assay. To generate mammospheres, single‐cell suspensions 
were maintained in mammosphere media as described before73 in Costar 3471 six‐well 
ultra-low attachment plates at a density of 5 × 103 cells/well. Number of mammospheres 
were counted and plotted as an average of three independent wells. 
3.5.9 Quantitative RT-PCR. mRNA was isolated from cells using the EZ-10 
DNAaway RNA Miniprep kit (Biobasic, catalog BS88133-50preps) and cDNA was 
synthesized using a kit (Azura Genomics, Catalog AZ-1996). RT-PCR was performed in 
an Applied Biosystems Quantstudio 6 Flex machine. Primer sequences were obtained from 
the Harvard Primer Bank.74  
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3.5.10 Immunoblotting. HMLER CD24low/β4low cells were either treated with 100 
nM of C6NP or left untreated for 72 hrs. Cells were lysed using Ripa buffer (Boston 
Bioproducts BP-115). Lysates were then separated on an 8% SDS-PAGE under reducing 
conditions. Membrane was blocked using 5% non-fat milk in Tris-Buffered Saline Tween-
20 (TBST). Primary antibody was stained overnight (N-cadherin: Abcam, AB7057, 
1:1000; Actin: Invitrogen, MA5-11869, 1:1000; Zeb1: Cell Signaling, 3396, 1:1000). Blots 
were washed three times in TBST before staining with secondary antibody for 2 hrs 
(Jackson Immunoresearch). Blot was imaged using chemiluminescence. 
3.5.11 Patient-derived Xenografts (PDX). PDX tumor established from triple-
negative breast cancer patient was dissociated using collagenase. Dissociated cells were 
passed through cell strainer and washed with PBS twice. Dissociated single cells were 
plated in presence of FBS for 30 min to remove mouse stromal cells to ensure no cells from 
the host animal contaminated the PDX cells. The floating cells were immunostained using 
CD44 and CD24 antibodies (Biolegend, 103006 and 311118 respectively) and FACS 
sorted into CD44high/CD24low (CSCs) and CD44 low /CD24 low (NCSCs) sub-populations. 
3.5.12 Cell Adhesion Assay. CD24low/β4low (CSCs) cells were treated with 100 nM 
C6NP for 72 h. Treated cells and untreated cells were plated at 40,000 cells per well on 
laminin 111 and laminin 511 treated tissue culture wells (3 µg of laminin per well). Cells 
were incubated for 2 hrs, at which time the plate was washed with PBS and stained with 
crystal violet. Stained plate was read on a DTX880 multimode detector (Beckman Coulter). 
3.5.13 ROS Detection. 105 cells were washed with Hanks’ Balanced Salt Solution 
(HBSS, Gibco) and pretreated with n-acetyl cysteine (NAC, 10 mM) for 15 min.  100 nM 
C6NP was then added for 30 min before adding H2DCFDA (Invitrogen) for another 20 
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min. After treatment, cells were washed twice with HBSS, suspended in 100 µL of HBSS 
and read on promega Glomax.  
3.5.14 Cell Viability Assay. CSCs and NCSCs were seeded at a density of 104 on 
a 96-well microplate for overnight attachment. The next day, cells either receive 2DG or 
C6NP or 2DG with 100 nM C6NP. After 2-day incubation, cells were washed once with 
PBS before adding 150 µL of 10% AlamarBlue solution. The plate was incubated in dark 
at 37°C for 3 h. 130 µL of supernatant was then transferred to a black plate for fluorescent 
reading at 560/590 nm.  
3.5.15 Synergy Computation. Synergy for each combination dose was calculated 
according to the Chou-Talalay synergy combination index (CI) metric.69 Computation was 
done using CompuSyn software, which is published by Combosyn, Inc. 
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HIGH-CONTENT AND HIGH-THROUGHPUT IDENTIFICATION OF 
MACROPHAGE POLARIZATION PHENOTYPES 
4.1 Abstract 
Macrophages are plastic cells of the innate immune system that perform a wide 
range of immune- and homeostasis-related functions. Due to their plasticity, macrophages 
can polarize into a spectrum of activated phenotypes. Rapid identification of macrophage 
polarization states provides valuable information for drug discovery, toxicological 
screening, and immunotherapy evaluation. The complexity associated with macrophage 
activation limits the ability of current biomarker-based methods to rapidly identify unique 
activation states. In this study, we demonstrate the ability of a 2-element sensor array that 
provides an information-rich 5-channel output to successfully determine macrophage 
polarization phenotypes in a matter of minutes. The simple and robust sensor generates a 
high dimensional data array which enables accurate macrophage evaluations in standard 
cell lines and primary cells after cytokine treatment, as well as following exposure to a 
model disease environment. 
4.2 Introduction  
Macrophages are plastic leukocytes that perform a vast range of immune- and 
homeostasis-related functions, with their function and behavior dictated by environmental 
stimuli. Macrophages can be characterized as being activated into two major phenotypes, 
M1 and M2.1 M1 macrophages are associated with inflammation, including secretion of 
pro-inflammatory cytokines, engulfment of foreign entities, generation of reactive oxygen 
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and nitrogen species, and assistance in T-helper type1 (Th1) cell responses to fight 
infection. Conversely, M2 macrophages perform anti-inflammatory and wound repair 
functions.2,3 Disturbance of the mechanisms that govern the balance of M1 and M2 states 
can result in a number of health problems, including infections, cancer, pregnancy 
complications, and inflammatory and autoimmune diseases.4,5 Given the significance and 
complexity of the roles macrophages play in biology and disease, knowledge of their 
activation and polarization state can provide critical information regarding the disease 
microenvironment, and be useful in selecting therapeutic approaches. For example, 
manipulation of tumor-associated macrophages (TAMs) provides a potential means to 
combat cancer. The tumor microenvironment releases factors that drive macrophages 
toward an M2-like phenotype, 6  resulting in secretion of anti-inflammatory cytokines, 
promotion of tumor growth and invasion, and facilitation of metastases. Therapies are 
being developed to “re-educate” these TAMs from this immune-suppressing state to an 
antitumor M1 phenotype as a more effective, less toxic cancer treatment. 7 , 8  The 
development of such entities would be facilitated by a means to evaluate macrophage 
characteristics in a straightforward and high-throughput manner. 
Efforts to generate therapies based on macrophage phenotypic conversion (to 
stimulate immune activation or suppression) and evaluate macrophage immunes responses 
to other agents in drug discovery and toxicology are challenging due to the complexity of 
the polarization process. An increasing body of research reveals that macrophage 
polarization is more intricate than a two-state, M1/ M2 conversion; rather, a spectrum of 
states exists.9-,10,11 M2 macrophages can be further subclassified into M2a, M2b, M2c, 
among others, depending on the activating stimulus and resulting surface markers 
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displayed.12 In addition, the macrophage polarization/sub-polarization process is dynamic 
and can evolve based on changes in the microenvironment.13-,14,15 Complicating the matter 
further, macrophages can have mixed or overlapping M1 and M2-associated indicators. 
For instance, macrophages isolated from patients with advanced gastric and pancreatic 
cancers show high levels of both pro-inflammatory and anti-inflammatory cytokines. Both 
sets expressed IL-10 (M2-associated), while the former also had high levels of IL-12, and 
the latter IL-1β and TNF-α (M1 associated).16,17 These factors make it challenging to 
identify macrophage polarization states for diagnostic applications and fundamentally, to 
understand or identify phenotypes that are relevant to disease states. 
Currently, the presence or levels of cellular and/or secreted biomarkers is most 
commonly used to detect and characterize macrophage polarization.18,19,12 While providing 
useful information, this approach is reliant on the specificity of the markers and requires 
multiple assays to obtain sufficient information for cellular evaluation. Additional 
limitations include: expression overlap between different polarization states (as mentioned 
above), poor phenotypic resolution of similar stimuli, non-translatable markers between 
mice and humans,12 and the fact that mRNA levels do not necessarily signal a robust 
difference in protein expression/at the functional level.19 In addition, the techniques used 
to identify the presence of biomarkers, such as RT-PCR, Western blot, and flow cytometry, 
are expensive and not amenable to multiplexing or high-throughput applications. Thus, 
there is a strong need for a general high-throughput method that can be used to evaluate 
these cells and their characteristics to facilitate therapeutic design and understand 
phenotypic responses of macrophages to stimuli.  
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As an alternative to marker-specific approaches, chemical nose or array-based 
sensing employs and discerns selective interactions between analytes and sensor elements 
to generate unique patterns for each analyte. The resulting pattern can be further analyzed 
for quantitative classification. Once trained, the sensor can rapidly identify analytes based 
on pattern recognition. This approach has been successfully used in a wide range of systems 
including mammalian cells,20-,21,22 bacteria,23-,24,25 and proteins in biofluids.26-,27,28 The 
strategy is ideal for cell phenotyping because changes in cellular responses yield variations 
in surface composition (e.g., protein, lipids, glycans, etc.) that result in different 
fingerprints, providing high-content information for each cellular state.29-,30,31 Because 
macrophage polarization is accompanied by changes in cellular metabolism and surface 
protein expression,1, 12, 32  we hypothesized that an array-based sensing strategy would 
provide a general platform for discriminating macrophage phenotypic and sub-phenotypic 
states. Incorporation of this strategy into a multi-channel format would enable 
multidimensional, high-content output from a single microwell, rendering this method 
readily applicable to high-throughput screening.33  
In this paper, we describe the development and application of a polymer-protein 
supramolecular assembly as a sensor array to gather high-throughput, high-content 
information on macrophage polarization state. The sensor is composed of only two 
elements: a guanidine-functionalized cationic poly(oxanorborneneimide) (PONI) polymer, 
and an anionic green fluorescent protein (GFP). The two entities form a complex through 
electrostatic interactions, resulting in a Förster resonance energy transfer (FRET) pair. 
When this sensor is applied to macrophages in different polarization/sub-polarization 
states, it yields fluorescent signals in five channels. The multidimensional output is then 
 
 71 
quantitatively analyzed using linear discriminant analysis (LDA) to reproducibly classify 
different macrophage activation states (Figure 4.1A). To the best of our knowledge, this 
combination of sensor elements resulting in a 5-channel output has not been reported 
previously. We validated the sensor with model macrophage RAW 264.7 cells and primary 
bone marrow-derived macrophages (BMDMs) stimulated with known M1 and M2 
polarizing cytokines. The successful discrimination of M1 and M2 macrophages among 
the five subtypes demonstrates the ability of the sensor to accurately differentiate subtle 
phenotypic changes. We further evaluated the efficacy of the sensor system in a model 
disease environment, where macrophages were cultured in cancer cell-conditioned media, 
generating distinct patterns for macrophages exposed to different cancer types. Taken 
together, the sensor platform can classify macrophage phenotypes in a matter of minutes. 
Furthermore, this platform can read out the effects of subtle environmental changes on 
macrophages, providing a new tool for diagnostics and for fundamental studies of 
macrophage behavior. The information generated can provide valuable insights on 
macrophages in diseases, potentially improving efficiency of existing therapies and 




Figure 4.1. Schematic illustration of phenotyping macrophage activation states using 
array-based sensor. (A) FRET-based sensor assembly was formed between PONI-C3-
Guanidine-Pyrene and GFP. Selective interactions of sensor elements at cell surface 
membrane resulted in fluorescence changes in all five channels, generating a distinct 
fingerprint for each cell activation state. (B) Chemical structure of PONI-C3-Guanidine-
Pyrene and the resulting five fluorescence channels in the FRET complex. 
4.3 Results  
4.3.1 Supramolecular assembly of sensor. The sensor is designed to provide an 
information-rich, five-channel output with only two sensor elements. The first element of 
the sensor is a cationic poly(oxanorbornene) (PONI) random copolymer scaffold that 
incorporates a guanidine group and a pyrene dye molecule (C3-Gu-Py). The positively 
charged guanidine group ensures that selective interactions occur only when the complex 
is close to negatively charged cell surface functionalities. The solvatochromic pyrene 
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molecule will alter its spectral properties when local environmental factors, such as polarity 
and hydrophobicity, change.34 In this way, both selectivity and sensitivity of the sensor are 
ensured. Through electrostatic interactions, cationic C3-Gu-Py forms a polymeric complex 
with an anionic GFP. In practice, the pyrene unit provides three signals, two corresponding 
to the free pyrene and one to the excimer form. The GFP then adds two channels: free GFP 
fluorescence and FRET with the two pyrene channels (Figure 4.1B).  
Initial studies focused on the optical characterization of the C3-Gu-Py/GFP 
supramolecular assembly. Polymer C3-Gu-Py was titrated with increasing concentrations 
of GFP. After 30 min of incubation, a simultaneous decrease in pyrene emission at 470 nm 
and increase of GFP emission at 510 nm was observed upon irradiation with 344 nm light 
(Figure 4.2A). Efficient fluorescence quenching of C3-Gu-Py was observed at higher 
concentrations of assembly (Figure 4.2B). The association constant Ka of 7.17 × 105 M-1 
was derived by fitting the fluorescent titration curve. 
 
Figure 4.2. Fluorescence titrations (A) and quenching (B) between C3-Gu-Py and EGFP. 
0.5 µM C3-Gu-Py was titrated with varying concentrations of EGFP in 10 mM HEPEs 
buffer. Fluorescence spectrum was recorded at pyrene excitation of 344 nm. A decrease in 
pyrene emission at 470 nm and increase of EGFP emission at 510 nm was observed. Each 




The overall spectrum featured five distinguished output peaks that can be recorded 
from the sensor: pyrene monomers at 344/390 and 344/420, pyrene excimer at 344/470, 
GFP at 475/510, and FRET signal at 344/510. Based on the spectral flexibility, a 
concentration of 0.5 µM C3-Gu-Py and 50 nM GFP was selected for the following 
experiments. Dynamic light scattering data revealed the polymer assembly was ~ 230 nm 
in diameter and the size slightly increased to ~237 nm when GFP was added. Transmission 
electron microscopy images confirmed these results, indicating that a supramolecular 
assembly was formed between C3-Gu-Py and GFP.  
4.3.2 Discrimination of M1 and M2 subtypes using RAW 264.7 cells. We first 
tested the ability of the sensor system to distinguish among macrophage phenotypes using 
the RAW 264.7 macrophage cell line. Established cytokines were used to stimulate the 
cells, with each activating macrophage through a different mechanism (Table 4.1), 
generating a distinct phenotypic state. RT-PCR results assessing standard M1 and M2 
markers confirmed that cells were polarized into corresponding states after 48 h activation 
(Figure 4.3). LPS and IFN-γ treated cells (M1 stimulation) showed significant increases in 
TNF-α and iNOS mRNA expression whereas the IL-4 (M2a stimulation) group had an 
increase in EGR2 and mannose receptor (MR) expression.  Similar TNF-α level observed 
between the combination treatment and the control group could be explained by the 
prolonged 48 hr activation time, negative regulators such as NFκB and nuclear factor 
activated T cells,35,36 greater production of nitric oxide, and the fast turn-over rate of TNF-
α.37 Although the IL-10 group (M2c stimulation) was tested against multiple M2 markers, 
including EGR2, MR, and TGF-β, as well as the reduction of M1 marker iNOS, no 
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significant changes in the levels of expression of any associated genes were observed 
(Figure 4.3B & 4.4). 
Table 4.1. Mechanisms and effects of in vitro macrophage polarization of macrophages 








Binds TLR 4, 
induces secretion of 
pro-inflammatory 
cytokines38 
Increased expression levels of 
MHC-II, CD80, CD86; decreased 
levels of MRC1 or Fc-γ RII39 
M1 
Interferon-γ (IFN-γ) Binds IFN-γ 
receptor40 
Combo (LPS + 
IFN-γ) 
Synergizes LPS and 
IFN-γ 





Decreased expression of 
CD14 and CCR5;41 regulation of 










Down-regulation of MHC II 




Figure 4.3. RAW 264.7 macrophage activation confirmed by RT-PCR. (A) mRNA 
quantification of M1-associated genes, TNF-α and iNOS. (B) mRNA quantification of M2-
associated genes, EGR2 and MR, according to treatment group. Control = non-treated cells, 
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combo = LPS + IFN-γ treated. Fold changes in mRNA level were normalized to β-actin. 
Statistical significance was determined by two-tailed student t-test. *= p < 0.1, **= p < 
0.05, ***= p < 0.005, n = 3 biological replicates. n.s. = not significant. 
 
 
Figure 4.4. RT-PCR quantification of M2 state in IL-10 activated RAW 264.7 
macrophages. TGF-β is M2-associated gene. Reduction of M1-associated gene iNOS is 
used to evaluate M2 state. Control = non-treated cells. Fold changes in mRNA level were 
normalized to β- actin. Statistical significance was determined by two-tailed student t-test. 
*= p < 0.1, **= p < 0.05, ***= p < 0.005, n = 3 biological replicates (3 technical replicates 
were used each). n.s. = not significant.  
 
Having confirmed that polarization had occurred, cells from each treatment group 
were plated on a 96-well microplate for overnight attachment. Equivalent cell numbers 
(10,000 per sample) were used to ensure that changes in sensor response were due to 
alterations in cell surface functionalities, not density. For the sensing process, C3-Gu-Py 
and GFP were premixed for 30 min to allow formation of stable FRET complexes. 
Subsequently, cells were washed once with phosphate buffered saline (PBS) and incubated 
with the sensor complex in the dark. Fluorescence signals were recorded every 15 min until 
equilibrium was reached. The 5-channel readout generated a distinct fluorescence pattern 
for each treatment group (Figure 4.5A). We further utilized linear discriminate analysis 
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(LDA) to test whether the six cell phenotypes could be robustly discriminated based upon 
their fluorescent signatures. As shown in Figure 4.5B, the LDA plot revealed six distinct 
clusters for M1 and M2 subtypes with a correct classification of 100%, demonstrating that 
each activation pathway resulted in a distinct cellular response. We further validated the 
reliability of the sensor by performing unknown sample identification and comparing the 
results against the training set. Among the 45 tested unknowns, 41 samples were predicted 
correctly into their corresponding group, giving a high percentage of correct unknown 
identification of 91%. The accuracy of unknown identification can be further improved by 
increasing the size and complexity of the training set.  Next, we investigated the necessity 
of having 5 channels of information from the sensor by comparing the performance of 
classification and unknown identification using either an individual sensor element or 
different combinations. The highest percentage of accuracy was achieved when all 5 
channels were used, demonstrating the importance of multidimensional data in 
discriminating complex cell phenotypes (Figure 4.5C). 
 
Figure 4.5. Discrimination of RAW 264.7 macrophages activated by M1 or M2 subtype 
stimuli using sensor complexes. (A) Fluorescence intensities of each treatment group were 
obtained at 30 min and normalized against sensor only. n = 8 biological replicates. (B) The 
fluorescence patterns were analyzed through linear discriminant analysis (LDA) and the 
first two canonical scores were plot-ted with 95% confidence ellipse (n=8). (C) Correct 
classification percentage and unknown identification of M1 and M2 sub-types using 




4.3.3 Discrimination of M1 and M2 subtypes with primary macrophages. 
Immortalized macrophage cell lines provide a useful tool for assessing sensor response, 
however, these models differ in multiple aspects from their primary cell analogs. We next 
tested the sensor using physiologically relevant primary bone marrow-derived 
macrophages (BMDM). Progenitor cells were isolated from C57/B6 mice and induced to 
differentiate into macrophages using previously reported procedures.43 Once macrophage 
cells were obtained, we exposed them to M1 and M2 subtype polarization stimuli for 48 h 
as used above for RAW 264.7 cells. RT-PCR results confirmed appropriate activations in 
each case, with increases in TNF-α and iNOS mRNA expression for M1 related stimuli 
(LPS and/or IFN-γ) and EGR2 and MR mRNA levels for IL-4 stimulated M2 cells. 
Although IL-10 activation did not show substantial enhancement in EGR2 level, a nearly 
6-fold increase in MR expression was observed (Figure 4.6). Following macrophage 
polarization, similar sensor procedure was performed. The fluorescence patterns observed 
were distinct from those of the RAW cells, suggesting differences exist in the two cell 
models. Complete discrimination among the five assessed groups of M1 and M2 
phenotypes was achieved with 96% correct classification (Figure 4.7). 92% of correct 







Figure 4.6. RT-PCR quantification activated primary bone marrow-derived macrophages. 
(A) mRNA quantification of M1-associated genes, TNF-α and iNOS. (B) mRNA 
quantification of M2-associated genes, EGR2 and MR, according to treatment group. 
Control = non-treated cells; combo = cells treated with both IFN-γ and LPS. Fold changes 
in mRNA level were normalized to β-actin. *= p < 0.1, **= p < 0.05, ***= p < 0.005, n = 
3 biological replicates (3 technical replicates were used each). n.s. = not significant.  
 
 
Figure 4.7. Discrimination of M1 and M2 subtypes of bone marrow-derived macrophages. 
(A) Fluorescence signals of the five sensor channels were obtained and normalized to 
sensor only. n = 8 biological replicates. (B) LDA plot of the first two canonical scores was 




When the sensor complex interacts with cells, in most cases, all monitored 
fluorescence channels showed an increase in signal intensity. This suggests that upon 
interacting with macrophages, the sensor complex disaggregates, exposing its individual 
components to interact with the cell surface. Depending upon the local environment, the 
fluorescence intensities for individual molecules (pyrene, GFP, and FRET) also change. 
Since distinct fluorescence patterns were consistently observed for each stimulus, we 
believe this disruption process is modulated by cell surface functionalities and 
composition. Our previous studies have indicated that the sensor complex is highly 
sensitive to glycosylation patterns on cell surfaces.30 However, more mechanistic studies 
are needed in order to elucidate which other cell components are also interacting with 
sensor elements. 
4.3.4 Discrimination of macrophages exposed to conditioned media from 
different cancer cells. The above studies demonstrate that our sensor array was able to 
discriminate macrophages polarized with specific cytokines. However, biological 
microenvironments are often far more complex and have multiple stimuli. Hence, we 
assessed whether the sensor could discern macrophage phenotype in a model disease 
environment to address this issue. First, conditioned media was generated by culturing 
different types of cancer cells (HeLa, cervical carcinoma, and MCF7, mammary 
carcinoma) until ~80% confluency was reached. Then, the culture media was extracted and 
used to stimulate macrophages for 48 h. RT-PCR results revealed different activation 
patterns for macrophages activated with media conditioned from different cell lines (Figure 
4.8). C3-Gu-Py and GFP complexes were added to cells and the 5-channel fluorescence 




Figure 4.8. RT-PCR quantification macrophages exposed to conditioned media from 
different cancer cells. (A) mRNA quantification of M1-associated genes, TNF-α and iNOS. 
(B) mRNA quantification of M2-associated genes, EGR2 and MR. Control = non-treated 
cells.  MCF7-M and HeLa-M = conditioned media from MCF7 and HeLa cells, 
respectively. Fold changes in mRNA level were normalized to β-actin. *= p < 0.1, **= p < 
0.05, ***= p < 0.005, n = 3 biological replicates (3 technical replicates were used each). 
n.s. = not significant.  
 
Distinct fluorescence signals were obtained for macrophages subjected to each of 
the conditioned media types. An LDA plot showed three well-separated clusters with 100% 
classification accuracy (Figure 4.9). When macrophages were exposed to cultured media 
conditioned by cervical cancer versus breast cancer cells, the sensing readout was 
dramatically different, indicating that a unique state of activation was present following 
each type of stimulation. A high percentage (96%) of correct unknown identification was 
also achieved. These results are exciting because it demonstrates that this method not only 
functions following single cytokine stimulation, but also in more complex environments. 
This is promising evidence that with careful evaluation, this sensing method could be 





Figure 4.9. Discrimination of macrophage cells cultured under exposure to conditioned 
media from different cancer cell types for 48 h. The LDA plot of the first two canonical 
scores was obtained and plotted with 95% confidence ellipses (n=8). CM is cancer cell 
conditioned medium, with the cell line type preceding it, control represent macrophages 
cultured using standard growth media. 
 
4.4 Discussion  
The Macrophage polarization is a complex and dynamic process. With its roles in 
homeostasis and disease, it is important to be able to discern macrophages characteristics 
in a rapid and straight-forward manner. Compared with current methods of characterizing 
macrophage polarization, the sensor reported in this study has advantages of generating a 
multidimensional and high-content chemical readout regarding the cell surface in a high-
throughput matter. Standard methods, such as RT-PCR and ELISA, can only capture a 
limited number of well-established markers for each cell activation state, and are 
independent (not multiplexed) assays, requiring a separate analysis for each. Considering 
the heterogeneity of macrophage polarization and the overlapping nature of M1 and M2 
markers,11,12 it is also difficult to elucidate and differentiate activation states with standard 
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methods. For instance, the multiple IL-10 markers used in our RT-PCR studies did not 
reveal significant changes. The ambiguity of a less-well characterized sub-phenotype could 
be because the end-point evaluation missed the dynamic changes on the macrophage 
marker expression during the 48 h activation. 
In contrast, the array-based sensor utilizes selective interactions between sensor 
elements and the entire analyte surface to generate high-content fingerprints for each 
activation state. Once trained, the sensor can rapidly identify target analytes through pattern 
recognition. Although the C3-Gu-Py moiety has been utilized for bacterial sensing,44 its 
capability in mammalian cell sensing has not been investigated. By coupling the polymer 
with simple GFP through supramolecular interactions, sensor can discern less-
characterized sub-phenotypes, such as IL-10 stimulated macrophages, which are 
challenging to identify using traditional methods like RT-PCR (Figure 4.5 & 4.7). The 5-
channel, high-content information gathered from the sensor is crucial in achieving a high 
level of classification accuracy and it allows us to address challenging biological questions 
from a chemical perspective. In addition, running assays like RT-PCR and ELISA can be 
time-consuming and error prone, with relatively high costs for thorough characterizations 
consisting of multiple markers. In contrast, the sensor material used here is synthetically 
easy to generate, and all components can be mixed in one microplate well, which not only 
reduces sensor material but is also compatible for high-throughput screening applications. 
What is more, accurate phenotyping can be obtained in less than an hour, making this 
method simple, robust, and rapid. 
Due to the robust and facile nature of the system, there are many potential 
applications for the array-based sensing strategy. Altered immune states are a major factor 
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in diseases including cancer, atherosclerosis, and auto-immune disorders. 45 -, 46 , 47 
Macrophage polarization states are key in driving forward disease progression. Rapid 
assessment of their activation states can provide valuable information in selecting 
appropriate therapeutic strategies.48,49 Notably, the high-throughput nature of the method 
would facilitate the rapid screening of immune states for individual patients, enabling 
personalized medicinal approaches in tackling these immune-driven diseases. Furthermore, 
this strategy could be applied to other plastic immune cells, such as dendritic cells and T 
cells.50,51 By extending this sensor to other cell types, the status of major components of 
the immune system could be rapidly determined. This strategy can also greatly improve 
the drug discovery process, by allowing for rapid identification of altered cell states, and/or 
evaluation of immunogenicity following agent treatment.52 Potential immune adjuvants or 
anti-inflammatory entities could be screened together by using the sensor on immune cells 
in a multi-well plate format. With these capabilities, the sensor system not only has utility 
as a fundamental research tool, but as a high-throughput, high-content means for 
therapeutic screening against general plastic cell types.  
4.5 Conclusion  
In summary, we demonstrate the use of a simple and robust chemical system that 
can quickly capture the overall responses of activated macrophages in a high-throughput 
format, which is challenging with biomolecular tools. Through the supramolecular 
assembly of only two elements, a 5-channel output is achieved. The high level of 
information density enables us to accurately profile a spectrum of activation state of 
macrophages. The ability to use chemical entities to answer biological questions opens the 
doors for sensing and beyond. 
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4.6 Experimental Section  
4.6.1 PONI-C3-guanidine polymer synthesis. Monomers and polymers were 
synthesized according to previous reports.53 Detailed synthetic scheme can be found in the 
supporting information.  
4.6.2 Dynamic light scattering (DLS). The hydrodynamic diameter of polymer 
and polymer-GFP complex were measured at 25 °C in 10 mM HEPEs buffer using a 
Malvern Zetasizer Nano ZS instrument. The measurement angle was 173° (backscatter). 
All samples were pre-incubated in DLS/zeta cuvette for 30 seconds at room temperature. 
The plots showed below were the average of three individual measurements. 
 
Figure 4.10. Hydrodynamic size of PONI-C3-Gu-Py polymer (A) and polymer-GFP 
assembly (B) in 10mM HEPEs buffer. C3-Gu-Py polymer formed a complex with an 
average diameter of 230 ± 84.4 nm. With the addition of EGFP, the size of polymer-EGFP 
assembly is approximately 237 ± 97.7 nm in diameter.  
 
4.6.3 Transmission electron microscopy (TEM). TEM samples were prepared by 
either 0.5 µM of C3-Gu-Py only or mixing 0.5 µM of C3-Gu-Py with 50 nM of GFP in 10 
mM HEPES buffer for 30 min in dark at room temperature. 5 μL of the solutions were then 
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placed on 300 mesh Copper grids (with formvar films) obtained from Electron Microscopy 
Sciences (EMS FF300-Cu) and allowed to dry overnight. The samples were analyzed using 
a TEM JOEL 2000FX at an acceleration voltage of 200kV. 
 
Figure 4.11. TEM image of PONI-C3-Gu-Py polymer (A) and polymer-EGFP assembly 
(B) in 10 mM HEPEs buffer. C3-Gu-Py polymer formed a complex of size ~25 nm. The 
difference in sizes measured by DLS and TEM can be attributed to the drying process 
during TEM sample preparation as well as the high vacuum conditions in the TEM 
chamber. Upon the addition of EGFP, larger complexes were observed. 
 
4.6.4 Green fluorescent protein expression. GFP was constructed and 
characterized according to reported protocols.54 In short, Escherichia coli strain BL21 was 
transformed with plasmids containing GFP recombinant protein. After transformation and 
induction with IPTG, cells were lysed and purified by Co2+ nitrilotriacetate columns. 
Fluorescent proteins were further characterized by SDS-PAGE gel, scanning absorbance 
and emission spectrum. The results are consistent with previously reported work.30 
4.6.5 Fluorescent titration. 0.5 µM C3-Gu-Py polymer was titrated with GFP at a 
concentration range from 0 to 200 µM in a black 96 well-microplate. The solution was 
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mixed in 10 mM HEPEs buffer. After 30 min incubation at room temperature in dark, the 
fluorescence spectrum was measured at an excitation wavelength of 344 nm. 
4.6.6 Binding affinity calculation. Fluorescence titration was utilized to calculate 
the binding affinity of the C3-Gu-Py polymer with GFP. The fluorescence decay of the C3-
Gu-Py excimer as a function of GFP concentration was fitted to a one-site binding 
equation,55 which is: 
 
where I is the fluorescence intensity of C3-Gu-Py excimer at a given concentration 
of GFP, I0 is the fluorescence intensity of C3-Gu-Py in the absence of GFP, Ilim is the 
fluorescence intensity when the quenching reaches a plateau, C0 refers to the concentration 
of C3-Gu-Py, and C is the concentration of GFP. Based on the equation, microscopic 
binding constant K was determined by using the non-linear least-squares curve fitting 
analysis in OriginPro (OriginLab Co., Northampton, USA). 
4.6.7 Linear discriminant analysis (LDA). LDA was applied on normalized 
fluorescence data to statistically classify each group, using SYSTAT software (version 
11.0, SystatSoftware, Richmond, CA, U.S.A.). All variables were used in the complete 
mode and the tolerance was set as 0.001. Input data was transformed to canonical scores to 
best separate each group where the between-class variance was maximized while the 
within-class variance was minimized. After transformation, LDA reduces the high 
dimension data to a lower dimension. The 2D plot pictorially shows where each data point 
lies in the new dimensional space. Therefore, the positive and negative values on the axis 
do not have any physiologically meaning other than a set of axes that separate out the input 
data.   
 
 88 
4.6.8 Unknown identification. The identity of unknown samples was predicted by 
computing the Mahalanobis distance of the unknown data to the training groups using 
LDA. 56  First, the normalized fluorescence responses of the unknown samples were 
converted to canonical scores in LDA, using the discriminant functions established from 
the reference set. Next, Mahalanobis distance of that case to the centroid of each training 
cluster in the LDA space was computed.56,57 The unknown sample was predicted to belong 
to the closest group, defined by the shortest Mahalanobis distance. 
4.6.9 Cell culture. RAW 264.7 cells, HeLa and MCF7 cell lines were purchased 
from American Type Culture Collection (ATCC, Manassas, VA). Primary bone marrow 
derived macrophages (BMDMs) were isolated from freshly euthanized C57/B6 mice, 
donated generously by Dr. Jessie Mager, Department of Veterinary and Animal Science, 
University of Massachusetts Amherst. The BMDMs were isolated, differentiated and 
cultured according to previously reported methods.43 All cells were cultured at 37 °C under 
a humidified atmosphere containing 5% CO2. Standard growth media consisted of high 
glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% antibiotics (100 µg/ml penicillin and 100 µg/ml streptomycin). 
Under the above culture conditions, the cells were sub-cultured approximately once every 
two to five days. 
4.6.10 Macrophage polarization via activation agents. Both RAW 264.7 cells 
and BMDMs were treated with the following polarization stimuli for 48 hours to induce 
the desired polarization state.  LPS group: 50 ng/mL, IFN-γ group: 50 ng/mL, Combo 
group: 50 ng/mL LPS and IFN-γ, IL-4 group: 30 ng/mL, and IL-10 group: 30 ng/mL. After 
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2-day polarization, cells were washed with PBS, trypsinized, and plated as 10,000 cells per 
well on a 96-well plate overnight before proceeding to sensing studies.  
4.6.11 Macrophage polarization via cancer cell conditioned media. HeLa and 
MCF7 cell lines were cultured under DMEM medium supplemented with 10% FBS and 
1% antibiotics for 2 days to reach above 90% confluency. The supernatant from each cell 
line was then collected and centrifuged for 5 minutes. Subsequently, 5 mL of the 
supernatant was transferred into a T25 culture flask containing RAW cells. After 48 hours 
of culture, RAW 264.7 cells were washed with PBS, trypsinized and plated as 10,000 cells 
per well on a 96-well plate for overnight attachment. 
4.6.12 Sensing studies. The sensor was prepared by mixing 0.5 µM of C3-Gu-Py 
with 50 nM of GFP in 10 mM HEPES buffer for 30 minutes in dark at room temperature. 
Subsequently, 150 µL of sensor solution was incubated with and without the cell 
populations (washed once with PBS) in 96-well microplates. The change in fluorescence 
intensity for each channel was recorded every 15 minutes at its respective wavelength 
(pyrene monomer: 344/390 nm and 344/420 nm, pyrene excimer: 344/470 nm, GFP: 
475/510 nm, FRET: 344/510 nm) on a Molecular Devices SpectraMax M2 microplate 
reader using appropriate filters. 
4.6.13 RT-PCR preparation. Cells were plated in 24-well plates at a density of 
50,000 cells/well. Cells were treated with the appropriate polarization stimulus for 48 h. 
Following treatments, RNA was extracted following the procedure below. 
4.6.14 RNA extraction and cDNA conversion. Approximately 1.5 µg RNA was 
harvested using the PureLink RNA Mini Kit (Ambion) following the manufacturer's 
instructions. SuperScript IV Reverse Transcriptase was used for the conversion of 
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approximately 150 ng of RNA to cDNA, along with RNaseOut, 10 mM dNTPs, and 50 µM 
Random Hexamers (ThermoFisher, Pittsburgh, PA), also following the manufacturer's 
instructions. 
4.6.15 RT-PCR Preparation. Cells were plated in 24-well plates at a density of 
50,000 cells/well. Cells were treated with the appropriate polarization stimulus for 48 hr. 
Following treatments, RNA was extracted following the procedure below. 
4.6.16 Quantitative RT-PCR. RT-PCR was performed on cDNA as prepared 
above using a CFX Connect real-time system with iTaq Universal SYBR Green Supermix 
(Biorad, Hercules, CA). All DNA primers were purchased from Integrated DNA 
Technologies (Caralville, Iowa). The following primer sequences were used: 
β-actin (forward) GATCAGCAAGCAGGAGTACGA,  
β-actin (reverse) AAAACGCAGCGCAGTAACAGT; 
iNOS (forward) GTTCTCAGCCCAACAATACAAGA,  
iNOS (reverse) GTGGACGGGTCGATGTCAC; 
TNF-α (forward) CCTGTAGCCCACGTCGTAG,  
TNF-α (reverse) GGGAGTCAAGGTACAACCC;  
EGR2 (forward) TGAGAGAGCAGCGATTGATT,  
EGR2 (reverse) ATAACAGTCAGTGTGTCCCC;  
Mannose Receptor (forward) GGATGTTGATGGCTACTGGA, 
Mannose Receptor (reverse) AGTAGCAGGGATTTCGTCTG;  
TGF-β (forward) GCGGACTACTATGCTAAAGA,  
TGF-β (reverse) TTCTCATAGATGGCGTTGTT.  
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Analyses were performed as follows: the samples were first activated at 50 °C for 
2 min, then 95 °C for 2 min. Then denaturing occurred at 95 °C for 30 s followed by 
annealing at 57 °C; the denature/anneal process was repeated over 40 cycles. Relative gene 
expression was determined by comparing the Ct value of the gene of interest to that of the 
β-actin housekeeping gene, by the 2ΔΔCt method. 58  Three biological replicates were 
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CONCLUSION AND OUTLOOK 
5.1 Potentials of array-based sensing in biomedical research 
 Over the past decade, numerus amount of research works has demonstrated array-
based sensing to be an effective strategy in extracting valuable information from 
challenging biological analytes. In this dissertation, I have developed and applied multi-
channel sensor arrays to profile phenotypically plastic cells including cancer stem cells and 
macrophages. Being able to quickly identify different cell states is an essential step for 
disease diagnosis. In addition, I have demonstrated the power of array-based sensing in 
high-content screenings with the example of how we identified a potential CSC 
differentiation inducer. Furthermore, the high-content information collected from 
macrophage polarization states can be applied in multiple areas of immunology including 
screening of immune states for individual patients, evaluating immunogenicity following 
agent treatment, and identifying the status of major components of the immune system. 
Taken together, array-based sensing strategy provides a simple and robust tool for cell 
phenotyping and holds promises in biomedical research.  
Despite the comprehensive information that array-based sensing can offer, there are 
still challenges that need to be addressed before translating the method into the real-world 
applications. One challenge that array-based sensing strategy faces in HCS and HTS is that 
the sensor needs to be synthetically easy to make and scale to a large quantity. The platform 
described in Chapter 4 is appealing, however, considering the storage condition and 
expression efficiency, the use of fluorescent protein still limits its application in large scale 
screenings. Materials such as polymers are a great choice if one can retain the sensitivity 
in an all-polymeric platform. In addition, due to the cross-reactivity among sensor 
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elements, not all sensor arrays reported are in a single-microwell, which is less ideal for 
HTS. Designing sensor arrays that can be mixed in one well not only reduces sensor 
material cost but also simplifies data collection and analysis steps. 
There has always been interests in understanding what the sensor arrays are 
responding to. As discussed in this thesis, the nature of the interactions between the sensor 
and cell surface is not well-understood. We have demonstrated in the past that the sensor 
arrays are sensitive to the glycosylation patterns on the cell surface, but other types of 
interactions are also possible. Combining the output of sensor arrays with advances in 
highly specific sensors will lead to better sensor design and expedite the biomarker 
discovery process. It is our hope that array-based sensing will offer a different perspective 
in studying challenging biological questions and open a new avenue for anticancer 
therapies.  
5.2 The role of α6β4 integrin in CSC differentiation  
 Integrins are αβ heterodimeric transmembrane proteins that interact with the 
extracellular matrix and transduce signals. They play essential roles in communicating cells 
with their microenvironments. Integrins have been found to be involved in a variety of cell 
signaling events including migration, invasion, proliferation, survival under both 
physiological and pathological conditions.1,2 Among the 24 different integrin receptors 
discovered (paired α and β subunits), β4 integrin subunit forms a heterodimer with α6 
subunit to bind with laminins in the extracellular matrix and facilitate the formation of 
hemidesmosomes. Previous research has reported that high β4 expression level is 
correlated with poor patient survival in many cancer types.3,4,5  In this thesis, we showed 
that upon EMT induction, β4 integrin expression was significantly decreased. Interestingly, 
 
 97 
the restoration of α6β4 reverted stem cell properties (Chapter 2). This result is further 
validated in the nanoparticle screening studies, where an increase in α6β4 integrin 
expression level was observed when CSCs were induced by the C6 nanoparticle to undergo 
differentiation (Chapter 3). These findings are consistent with the previous work that the 
expression of β4 subunit is low in CSCs as compared to non-CSCs. 6  In sum, α6β4 
coherently shows its importance in destemming CSCs/promote differentiation. 
 However, conflicting data on the function of β4 integrin in CSCs has been reported. 
In 2017, Bierie et al. discovered that the mesenchymal cell population could be further 
stratified into two sub-populations based on integrin β4 expression level. Although β4hi 
cells have more epithelial traits and β4lo fraction has more mesenchymal traits, both 
populations showed equivalent mammosphere formation ability. Interestingly, we 
observed that β4lo cells retained their self-renewal abilities over a few passages, whereas 
β4hi cells gradually lost this ability (Chapter 3). In addition, their results demonstrated that 
although β4lo cells are more mesenchymal in morphology and have higher EMT-associated 
gene expressions, they are actually less tumorigenic than β4hi cells.  
 The conflicting results could be due to the different methods used for enriching 
mesenchymal cells. As shown in Figure 5.1, the results from Bierie et al. were obtained 
using naturally arising mesenchymal cells (NAMEC) derived from immortalized, non-
tumorigenic human mammary epithelial (HMLE) cells, whereas we used HMLE cells 
transformed with H-Ras oncogene (HMLER). The different enrichment methods could 
result in different EMT states. Since it is rare for cells to reside in a fully mesenchymal 
state via an EMT,7 it is likely that the NAMEC and HMLER cells were at different partial 
EMT states with heterogeneous cell dynamics before integrin sorting. Even though these 
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cells were sorted based on the same set of surface markers (CD24, CD44, ITGB4), the 
resulting subpopulations were not identical to each other in the comparison. In other words, 
the CD44hiCD24loβ4lo cells, which have the less tumor-initiating ability in Bierie et al. 
study, are not the same population with stem properties in our studies.  
 
Figure 5.1. Different isolation and CSC enrichment methods. Both mesenchymal cell 
populations (HMLER and NAMEC) were derived from immortalized, non-tumorigenic 
human mammary epithelial cells (HMLE) and further sorted into two subpopulations based 
on integrin β4 level. 
 
 These conflicting results are interesting because they suggest that CSCs and their 
tumor-initiating ability is a complex property that cannot be solely determined by surface 
markers. This hypothesis is partially supported in the same paper, where the opposite trend 
of tumor-initiating abilities in integrin β4 subpopulations is observed with MDA-MB-231 
cells. In fact, research in other tumor types has also shown contradictory results when using 
CSCs enriched from different cell lines. In glioblastoma stem cells, some reported 
undetectable level of β48 whereas others reported an elevated level of expression.9 The 
difference is that the former study used CD133-enriched glioblastoma stem cell 
tumorspheres whereas the latter used mammospheres derived from glioma cell line LN229 
to conduct CSC-related work. Therefore, consistent detection and isolation methods are 
needed as we gain more insights into CSC biology. 
   
 
 99 
5.3 Alternative CSC detection methods and screening application 
 Although CSCs are typically defined and isolated by surface markers, in the past 
decade, there is an emerging trend of seeking alternative detection and isolation methods. 
In a recent study, a small population of cells with intrinsic autofluorescence was identified 
from freshly isolated primary epithelial tumors. These cells display functional features of 
CSCs including self-renewing, highly tumorigenic, and chemo-resistant. Mechanistic 
studies suggest that the autofluorescence comes from the membrane-bound cytoplasmic 
vesicles. This study proposes the intracellular auto-fluorescent vesicles to be a new 
functional marker for CSC isolation and detection through flow cytometry.10 In a separate 
study, a group of researchers developed a microfluidic device to isolate breast CSCs 
utilizing the EMT property of enhanced cell migration, The trapped migratory cells were 
shown to have a higher tumor-initiating ability and more metastatic than the non-migratory 
cells.11 
 The distinct sensing patterns of subpopulations of mesenchymal cells from both S1 
and HMLER CSC models (Chapter 2 and 3) suggest that array-based sensors can 
discriminate cells with different cell surface components. It would be interesting to test 
whether the sensor arrays demonstrated in this thesis would sense the above-mentioned 
functionally different subpopulations of CSCs, and the auto-fluorescent cell populations of 
CSCs. If so, the complex microfluidic device, labor-intense cell imaging, and flow 
cytometry could be avoided, hence increasing the throughput of detecting CSCs.  
 The sensing screen demonstrated in Chapter 3 has proven its application in 
identifying novel CSC differentiation inducers. In this thesis, we only explored the 
hydrophobic effect on CSC differentiation. In the future, it is promising to strategically 
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build the screening library to increase the likelihood of identifying compounds that induce 
the change in CSC phenotype. Since epigenetic regulators, such as Bmi1 and HDAC, have 
been shown to be important for CSCs to acquire stemness (Chapter 1.3.3), incorporating 
epigenetic inhibitors into the library seems promising. In addition, CSCs have been 
reported to contain lower levels of ROS than non-CSCs, thus, screening compounds that 
targets the higher expression of ROS scavengers may be an efficient way of changing CSC 
properties.  
5.4 Tumor microenvironment  
 In this thesis, we demonstrated that that different tumor microenvironments could 
differentially activate microphages into distinct phenotypic states (Chapter 4). Such 
influence is complicated and being able to dissect out the key players involved in the 
process is a fundamental question to be addressed. Cancer-associated fibroblasts (CAFs) 
are a major component of the tumor microenvironment. Increasing amount of evidence 
have shown the crucial roles that CAFs play in modulating the immune system and 
influencing the tumor microenvironment, including polarizing T cells and macrophages, 
and recruiting B cells. 12  It is interesting to explore how CAFs synergize with tumor 
associated microphages (TAMs) and influence microphage polarization. Although CAFs 
can induce M1 to M2 trans-differentiation, specific communication cues remain to be 
elucidated. Identifying key factors that are involved in such process will help develop 
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